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Abstract 
Increased arterial stiffness is associated with ageing, cardiovascular disease diabetes 
and renal failure.  
The aims of this thesis were to investigate the reproducibility of a tissue Doppler 
imaging (TDI) based ultrasound system to calculate indices of arterial stiffness, and to 
investigate changes in arterial wall stiffness in subjects with increased age, peripheral 
arterial disease (PAD), chronic kidney disease (CKD) and angiotensin converting 
enzyme inhibitors (ACE-Is). 
A reproducibility study demonstrated good reproducibility. A study of healthy 
subjects demonstrated a stronger relationship with age for arterial stiffness than intima 
media thickness (IMT). Case control studies investigating changes in subjects with PAD 
and CKD demonstrated a greater increase in arterial stiffness than IMT when compared 
to healthy controls. An epidemiological study, investigating the effect of anti-
hypertensives on collagen turnover, suggested an association between increased 
collagen turnover and ACE-Is. Investigating the effect of ACE-I administration on arterial 
stiffness in subjects with PAD, we demonstrated an increase in collagen turnover and a 
decrease in arterial stiffness.  
We have demonstrated that the TDI-based system is a reproducible method of 
measuring arterial stiffness. We suggest that arterial stiffness increases more than IMT 
with ageing, PAD and CKD and that it may increase before cardiovascular disease 
develops. 
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1 
BASIC PRINCIPLES OF ARTERIAL STIFFNESS 
Arterial stiffness is a generic term that describes the rigidity of the arterial wall. The 
arterial wall is structurally made up of three layers, with varying degrees of elasticity 
which is present to counter the pulsatile ejection of blood from the heart. The majority of 
research in arterial stiffness is based on elastic theory. The application of elastic theory 
to arterial stiffness assumes that the arterial wall is heterogeneous and moves 
isotropically.  Whilst this may not be the case, these assumptions have been allowed as 
research into arterial stiffness would otherwise not be practicable on a clinical level.  
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Definition of arterial stiffness 
Large arteries are not just simple conduits for blood. In addition to this 
function, they also act as a buffer to the pulsatile blood flow from the 
heart. This role is fulfilled via the elastic nature of the arterial walls. 
Detailed assessment of the arterial tree requires information about the 
form of the arterial pulse (i.e. the arterial pressure waveform) and 
information about how the arterial walls move in reaction to this waveform 
(i.e. the arterial distension waveform). At the most basic level, palpation 
of an arterial pulse can convey a crude impression of these two 
parameters. Records of the clinical importance attached to the qualitative 
assessment of the pulse have been present for nearly two hundred 
years.1 Qualitative assessment declined in the 19th century with the 
development of accurate sphygmomanometry, collecting quantitative 
information about the extremes of the pulse.2,3 In the past three decades 
as new technology and understanding has become available, attention 
has once more focused upon the qualitative assessment of the arterial 
waveforms and their potential clinical relevance. Many terms exist in this 
field, often with slightly different interpretations and commonly referring to 
a distinct physical equation or property. Arterial stiffness has been chosen 
as a generic term in this thesis to avoid confusion and describes the 
describes the rigidity of arterial walls.4 
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Arterial structure 
All arteries are composed of three layers, the intima, media and 
adventitia. The intima is the innermost layer, a single layer of endothelial 
cells and associated connective tissue. The middle layer is the media 
which is composed of a varying amount of elastic and smooth muscle 
tissue depending on the size and location of the artery in the arterial tree. 
The outer layer is the adventitia which is fibrous connective tissue. 
 
Figure 1: Structure of a medium sized artery. 
(after Kangasniemi & Opas)5 
Mechanical principles 
A force (stress) acting on a solid body at rest causes parts of the body to 
move relative to each other (strain). At the end of the application of the 
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force, if the body regains its original form, then it is said to be elastic. If 
the body retains the deformation caused by the force acting upon it then it 
is said to be plastic. 
Strain 
Strain is described is as the ratio of the de-formation of a body compared 
to its original form and thus has no units. Longitudinal strain is defined as 
the change in length of a body in response to stress. An increase in 
length is positive strain and a decrease in length is negative strain. 
Compressive strain refers to a change in volume of a body and sheer 
strain to angular deformation, a displacement of two points in parallel 
planes in a direction parallel to those planes.6 As demonstrated in Figure 
2, a body that is extended longitudinally (longitudinal strain) will at the 
same time get shorter transversely (transverse strain). 
The ratio of transverse to longitudinal strain is called the Poisson 
ratio (σ). σ for a particular material is constant under small strain. The 
effective range for σ is 0 to 0.5.  In a small extension of a material with a 
ratio of 0.5, the volume of the material remains the same when stretched. 
This is known as iso-volumetric deformation, and it is exhibited by rubber-
like substances where σ = 0.48.7 σ for the arterial wall is believed to be 
close to 0.5.8 
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Figure 2: Longitudinal (or tensile) strains. 
 
 Legend: (A) An elastic solid of dimensions X0, Y0, Z0 in the unstrained state before 
deformation (solid lines) and after a positive tensile strain εxx resulting from the tensile 
stress Xx (broken lines). Strains in the y-axis and z-axis are εyy and εzz respectively and 
are both negative. (B)Shearing strain produced by the stress Xy. One measure of strain 
is the angle of shear, Φ. (After Mcdonald)6 
 
However it cannot be assumed that the Poisson ratio in all planes 
of a material is similar.  Considering a cube shaped section within the 
body of a material it can be shown that there are six independent 
components of strain.9 If the material has the same elastic properties in 
all planes then it is said to be isotropic. Conversely if the elastic 
properties are not the same the material is said to be anisotropic. If the 
elastic properties in each direction are not the same but however the 
material is iso-volumetric under strain then the average values of σ must 
be equal to 0.5. 
Elastic theory 
Elastic theory attempts to explain the relationship between the force 
applied to a body and its consequent change of deformation. The 
behaviour of a body in response to a stress distinguishes solid from liquid 
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as a liquid will undergo viscous flow whereas a solid will not.  However a 
large number of bodies are termed viscoelastic as they exhibit qualities 
attributable to both an elastic solid and a viscous liquid; their behaviour in 
any given situation depends on the size of the stressing force and the 
rate at which it is applied.  Arterial walls are viscoelastic.6 
Hooke's law10 dictates that the deformation is proportional to the 
force applied and this holds true in an elastic body until it reaches its 
elastic limit which is the point at which the force applied to a body is so 
great that it cannot regain its original form. Further increase of load would 
result in the yield point being reached where the body will break without a 
further increase in force. The application of elastic theory on a solid body 
can only be valid below the elastic limit of that body, and also requires 
that the material structure of that body is homogeneous and that any 
deformations as result of the applied force are minute (that the body 
returns to its original form when the force is removed). These two 
assumptions are clearly not valid when considering arterial walls. Arterial 
walls retain large deformations, and as discussed previously are 
composed principally of collagen, elastin and smooth muscle which all 
have different elastic properties. Despite these limitations, most work on 
arterial mechanics uses elastic theory as its basis, as this is the simplest 
model that is most easily applied to arterial wall movement. 
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Stress 
Stress is the intensity of a force acting over a given area of a body and 
thus the units of stress are force per unit area. The effect of stress on a 
point in a plane can be described by forces acting in parallel to the axis 
and acting tangentially to the axis. These forces can be resolved into six 
independent components of stress. Given that Hooke's law10 
demonstrates that strain is proportional to stress, in an anisotropic 
material there are 36 constants of proportionality as there are six 
components of strain and six components of stress acting at any one 
point on a body. Fifteen of these constants can be shown to be 
interrelated. Thus in an anisotropic material, 21 constants need to be 
considered. An isotropic material however has the same elastic behaviour 
in all three axes and thus the number of constants of proportionality 
becomes 2 instead of 21. It is immediately apparent therefore why arterial 
walls are assumed to be isotropic even though structural analysis 
demonstrates different macro- and microscopic components.  
Circulatory model 
One of the earliest and simplest models for the arterial system was first 
published by the Rev Stephen Hales in his book entitled Haemostaticks in 
1733.11 This model demonstrates how the major arteries act as a cushion 
or buffer to the intermittent pumping of the heart. Combining this property 
with the high peripheral resistance of the arterioles, this explains how the 
flow of blood at the tissues is near constant and virtually devoid of cardiac 
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pulsation. This model (shown in Figure 3) is termed the Windkessel 
model after the mediaeval German fire compression chamber which 
illustrated the German translation of his work. 
Figure 3: Diagram of the Windkessel model for the arterial circulation. 
 
Legend: A pulsatile pump, pumping into a pressure vessel partly filled with air which 
thus acts as a capacitor. The output is via a high resistance pipe and the result is a near 
constant outflow despite the pulsatile inflow. P= pulsatile pump; V=one way valve; 
C=capacitor; R= high resistance pipe. (after Greenwald)12 
 
Clearly the properties and function of the arterial system are much 
more complex than this. In particular, the approximation together of total 
arterial compliance and total peripheral resistance is a gross simplification 
which does not reflect anatomical knowledge of the arterial tree. 
Nevertheless the Windkessel model does help to explain how arterial 
elasticity fits into the function of the arterial system under normal 
physiological conditions. 
The circulation actually distributes cardiac output via a series of 
branching networks, and this model serves to explain the concept of 
wave reflection. At every branching of an artery, a small proportion of the 
forward travelling pulse wave is reflected backwards. Thus the arterial 
waveform is a summation of both the forward travelling pulse wave and 
9 
 
the reflected wave travelling back towards the heart. This quality may 
have a significant effect on systolic blood pressure,13 and perhaps explain 
the systemic cardiovascular changes that are found in subjects with 
peripheral arterial disease (PAD).  
Conclusions 
Arterial stiffness is a generic term that describes the rigidity of the arterial 
wall. The physiological reason for the elastic nature of the arterial wall is 
to buffer the pulsatile ejection of blood from the heart and to provide near 
constant flow in the capillary beds. The mechanical principles behind 
arterial stiffness are complex but are based on the relationship between 
stress and strain. In the case of arterial stiffness, the stressing force is the 
pressure of pulsatile blood flow and the resulting strain is the change in 
length of the arterial wall. Most work on arterial stiffness is based on 
elastic theory despite the fact that this requires the body studied to be 
elastic rather than viscoelastic as is the case with the arterial wall. In 
addition, the arterial wall is considered to be isotropic in response to 
stress as this permits much simpler calculation of indices of arterial 
stiffness. 
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2 
INDICES OF ARTERIAL STIFFNESS 
All indices to calculate arterial stiffness require information about simultaneous change 
in pressure and distension of the target artery. There are many defined indices, with 
relative advantages and disadvantages. Most modalities used to collect data are non-
invasive. The most widely accepted method is aortic pulse wave velocity collected using 
applanation tonometry. Indices of arterial wall stiffness can be collected using ultrasound 
which may have the greatest application in research settings comparing them to IMT. 
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Introduction 
There are many indices of arterial stiffness.  All require information about 
simultaneous change in arterial size and arterial pressure in order to 
quantify the change in arterial stiffness.  The change in arterial size may 
be calculated as the change in diameter or change in volume. Both of 
these parameters should be measured at the same site in the arterial tree 
due to discrepancy in values across the arterial tree, although in vivo this 
may be practically impossible.14 As in most cases of equipoise, the 
existence of multiple indices for quantifying arterial stiffness reflects the 
fact that none of them are superior to one another; all have inherent 
advantages and disadvantages. 
Pulse pressure 
Pulse pressure (PP) is the difference between systolic and diastolic blood 
pressure. It has long been recognized as a valuable surrogate marker of 
arterial stiffness15 as it depends on cardiac output, large artery stiffness 
and wave reflection. Both systolic and diastolic blood pressure increase 
with age. However, beyond the sixth decade, diastolic blood pressure 
does not increase where as systolic blood pressure continues to do so 
and thus pulse pressure increases with age.13 Pulse pressure takes no 
account of change in volume and therefore is not a true measure of 
arterial stiffness. Moreover, most measures of pulse pressure are made 
from the brachial artery using an oscillometric sphygmomanometer. 
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These measurements may not accurately reflect central pulse pressure, 
with differences of up to 20 mmHg noted.16,17 Nevertheless, data from the 
Framingham study demonstrates that pulse pressure predicts the risk of 
coronary heart disease better in a population over the age of 50 years 
than systolic or diastolic blood pressure measurements alone.18 
 Arterial compliance and distensibility 
Arterial compliance is defined as a change in volume for a given change 
in pressure and is defined by the following formula: 
 
∆d/∆p m/KPa  
 
Arterial distensibility is defined as compliance divided by the initial 
volume: 
 
∆v/(∆p×v) KPa-1  
Where v = volume 
  
When considering pulsatile flow (which is obviously the case with 
arteries in vivo) many researchers have considered that compliance and 
distensibility can be estimated using the change in radius, diameter, flow 
or cross-sectional area for a given change in pulse pressure as long as 
both of these variables are measured at the same site in the arterial 
tree.19,20 Various other estimations of compliance and distensibility using 
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stroke volume and pulse pressure have been demonstrated to be 
inaccurate and have been discredited.21 
Elastic moduli 
The relationship between stress and strain is expressed as an elastic 
modulus. All elastic moduli express the units of stress, as strain is a ratio 
and therefore has no units.  
Pressure strain elastic modulus 
The pressure strain elastic modulus (Ep) was first presented by Peterson 
et al in 196022 as a modulus which did not require knowledge of wall 
thickness in order to be calculated, and is calculated by the following 
formula:  
Ep = (∆p*d)/∆d  KPa 
where d is diameter, ∆p is the difference pressure at systole and diastole 
and ∆d is the difference in diameter at systole and diastole. 
Young's modulus 
Young's  modulus (E) is the elastic modulus in the longitudinal direction of 
a material and was named after Thomas Young.23 It requires knowledge 
of wall thickness to be calculated and is defined by the formula: 
 
E = (d/2h)*Ep  KPa 
Where h is wall thickness. 
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There is discrepancy in the literature as to the exact form that E 
should take when applied to arterial stiffness. Different editions of the 
same book even present a different formula. However the author is 
confident that the formula quoted in this thesis is correct. This statement 
is reinforced by a literature search and by kind help from the department 
of Medical Physics at Edinburgh University, whose members have 
derived the formula from first principles (see Appendix 1). 
Ep is regarded as a measure of structural stiffness, describing the 
elastic behaviour of the artery as a whole and E as a measure of material 
stiffness which describes the behaviour of the arterial wall itself.24  
 
 
Stiffness index 
The stiffness index was introduced by Kawasaki et al25 as an index of 
arterial stiffness independent of pressure. It is described by the following 
formula: 
 
ln(ps/pd)/(ds-dd/dd) 
where ps= systolic pressure, pd = diastolic pressure, ds= systolic diameter, 
dd= diastolic diameter 
 
It is based on work by Hayashi et al24 who found a linear relationship 
between the logarithm of relative pressure and the distension ratio when 
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examining isolated human arteries in vitro. Hayashi and colleagues argue 
that the slope of this exponential function describes the behaviour of the 
arterial wall within the in vivo pressure range without dependence on 
pressure. 
Augmentation index 
The shape or contour of the ascending aortic pressure wave has been 
classified  and has been shown to change in morphology with increasing 
age.26 The main change is the point of peak systolic blood pressure and 
its relationship to the inflection point on the waveform representing the 
reflected pressure wave. The augmentation index is defined as the ratio 
of augmented ascending aortic pressure and pulse pressure and can be 
calculated from the following formula: 
 
(ps – pi)/(ps- pd),pd) 
where pi is pressure at the  wave reflection.  
 
This method of estimating arterial elasticity has been used in several 
studies.27 However it has many limitations including erroneous results 
when an inflection point is not easily identified.28 In addition the 
augmentation index is also influenced by heart rate. 
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Pulse wave velocity  
Pulse wave velocity (PWV) is an indirect measurement of arterial stiffness 
over an arterial segment.  It is measured using applanation tonometers 
such as the Complior (Colson, Paris, France) and the SphygmoCor (PWV 
Medical PTY Limited, Sydney, Australia). PWV is calculated by the 
following formula: 
 
PWV = distance/∆t  ms-1 
where t = time 
 
The transit time is measured by two applanation tonometers placed over 
peripheral pulses and the distance between them is estimated by direct 
superficial measurement. This estimation is subject to inaccuracy unless 
the artery between the two pulses is in a straight line and can be difficult 
to make particularly in the case of obese patients.21 PWV is related to 
Young's modulus: 
 
PWV = √(E x h/2rp)  
where p is the density of fluid (approx 1.05 for blood).29 
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Conclusions 
There are numerous formulae to calculate arterial stiffness. All require 
information about change in pressure and size, and are summarised in 
Table 1.  
Table 1: Indices of arterial stiffness 
Term Definition Mode of Measurement 
 
pulse pressure 
 
the difference between systolic and 
diastolic blood pressure 
 
ps- pd 
 
sphygmomanometry 
 
 
arterial compliance 
 
absolute diameter(or area) change 
for a given pressure step  
 
∆d/∆p  m/KPa 
 
ultrasound  
MRI 
 
 
arterial distensibility 
 
relative change in diameter (or 
area) for a given pressure change, 
the inverse of elastic modulus  
 
∆d/(∆p×d)  KPa-1  
 
 
Ultrasound  
MRI 
 
elastic modulus the pressure change required for 
theoretical100% stretch from 
resting diameter 
 
(∆p×d)/∆d  KPa 
 
Ultrasound  
MRI 
 
Young’s modulus Elastic modulus per unit area 
 
(∆p×d)/(∆d×h)  KPa 
 
Ultrasound  
MRI 
augmentation index 
 
difference between the second and 
first systolic peaks as a percentage 
of pulse pressure 
 
(ps – pi)/(ps- pd)  
 
pressure waveform 
stiffness index ratio of the log of systolic/diastolic 
pressures to relative change in 
diameter 
 
ln(ps/pd)/(ds-dd/dd) 
 
ultrasound 
pulse wave velocity velocity of travel of the pulse along 
a length of artery 
   
distance/∆t  ms-1 
pressure waveform 
ultrasound 
MRI 
Legend: p=pressure; d=distance; h=thickness diameter; t=time; s=parameter measured at systole; 
d=parameter measured at diastole; pi=pressure wave reflection. 
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3 
MECHANISMS OF ARTERIAL STIFFNESS 
Change in arterial stiffness can be mediated by change in either the structural and 
cellular components of the arterial wall or both. The changes in the structural component 
of the arterial wall tend to be long term and irreversible, as a result of a change in the 
quantity and quality of collagen and elastin. The cellular component of arterial stiffness 
changes as a result of vascular smooth muscle tone and endothelial cell function. This 
may be part of physiological control of the cardiovascular system and may be reversible. 
There are many putative genetic loci for genetic causes of arterial stiffness. 
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Introduction 
The mechanisms of arterial stiffness are complex and interactive. 
Stiffness develops due to a combination of reversible and irreversible 
changes in the structural and cellular elements of the vessel wall, and are 
summarised in Figure 4.  
Figure 4: Summary of the multiple causes and locations of arterial 
stiffness 
 
Legend: ↑=increased; ↓=decreased; AGE=advanced glycation end product; MΦ= 
macrophage; I-CAM=intracellular adhesion molecule; MMP=matrix metalloproteinase; 
TGF-β= tissue growth factor beta; VSMC=vascular smooth muscle cells. (After 
Zieman)30 
 
These changes are influenced by various haemodynamic 
forces31,32 resulting from the flow of blood through the arteries, which 
results in a patchy periphery sparing distribution of arterial stiffness within 
the vascular tree,33-37 and by so-called 'extrinsic factors', notably 
hormones, salt and glucose regulation. In turn common chronic disease 
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states such as hypertension, renal failure and diabetes mellitus can 
exacerbate these mechanisms.  
Structural changes in arterial stiffening 
The structure and compliance of the arterial wall is dependent on the 
relative proportions of collagen and elastin, the two major proteins making 
up the extracellular matrix (ECM). The relative proportion of these two 
proteins is maintained at near constant levels in health via homoeostasis. 
Dysregulation, usually stimulated by an inflammatory milieu, leads to 
decreased production of elastin and overproduction of abnormal collagen, 
thus resulting in increased arterial stiffness.38 The main method by which 
collagen and elastin are degraded is by matrix metalloprotease (MMP) 
production. MMPs cause degradation of collagen and elastin via their 
collagenolytic and elastinolytic effects. Thus MMPs degrade the ECM by 
creating uncoiled collagen and broken and frayed elastin. MMPs are 
produced by vascular cells and macrophages and polymorphonuclear 
neutrophils.39 The potent catabolic effect of MMP is countered by tissue 
inhibitors of MMPs.33,40 This role is vital in maintaining collagen and 
elastin homoeostasis. 
The main role of collagen is to provide tensile strength to the 
arterial wall. Collagen molecules are enzymatically cross-linked soon 
after production. Damage to these cross-links will cause unravelling of the 
collagen matrix. The turnover of collagen is slow and susceptible to non-
enzymatic ligation cross-linking, resulting in an increased quantity of 
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collagen with a dysfunctional matrix. Hypertension, manifesting as 
increased luminal pressure also stimulates excessive collagen 
production.41 Elastin is also cross-linked to promote stability. Damage to 
these cross-links causes weakening of the elastin array and also 
predisposes to demineralisation by calcium and phosphorus. Together 
with decreased production and repair of elastin, these factors all result in 
increased arterial stiffness.42-44 
Advanced glycation end products (AGEs) arise as a result of non-
enzymatic protein glycation. These products form irreversible cross-links 
in proteins such as collagen with slow turnover.45,46 AGE-linked collagen 
is stiffer per se and also less easily degraded, resulting in an increased 
proportion of this type of collagen in the arterial wall.47 Elastin molecules 
are also susceptible to AGE cross-linking, resulting in a less effective 
elastic matrix.48  AGE also has an effect on endothelial cell function and 
inflammatory response, resulting in increased generation of oxidant 
species, oxidant radical formation, pro-inflammatory cytokines and 
vascular adhesion molecules.49,50 These substances can mediate 
increased vascular stiffness via MMPs, provoke endothelial dysfunction 
and thus elevated smooth muscle tone, depress endothelial flow 
mediated dilatation, diminish response to vascular injury, affect 
angiogenesis and promote atherosclerotic plaque formation.51-53 These 
molecular changes are visible on a macroscopic level as increased intima 
media thickness54 (IMT) and hypertrophy of the smooth-muscle layer.55            
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On a microscopic level the intima of diseased vessels demonstrate 
abnormal and disarrayed endothelial cells, an increase in collagen, frayed 
and broken elastin molecules, infiltration of vascular smooth muscle cells 
and an increase in macrophages, mononuclear cells, MMPs, cytokines 
and cell adhesion molecules.56 
Cellular component of arterial stiffening 
As well as changes to the structure of the arterial wall, arterial stiffness 
can also lead to altered vascular smooth muscle cell (VSMC) tone and 
endothelial cell function. VSMC tone can be influenced in a number of 
ways, including mechanical stimulation causing cell stretching and 
changes in calcium signalling30 and also by angiotensin II,57 endothelin,58 
oxidant stress59 and nitric oxide. The main effect of endothelial 
dysfunction appears to be an imbalance in production and breakdown of 
vasodilating and vasoconstricting substances notably nitric oxide, 
oxygenators and constricting hormones.60 In particular, levels of nitric 
oxide may be altered as a result of reduction of expression, increased 
expression of a natural nitric oxide synthase (NOS) inhibitor, 
asymmetrical dimethylarginine,61 and activation of reactive oxygen 
species by stress, hormones and AGEs.62 
There is evidence that structural stiffening itself may result in 
endothelial dysfunction as endothelial cells cultured in expansile tubing 
and subjected to pulsatile perfusion demonstrate stimulation of 
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endothelial NOS expression; this expression is not found when the cells 
are cultured in stiff tubing but still subjected to the same pulsatile flow.63 
Genetic implications 
Given its multifactorial nature, it will come as no surprise that more than 
one genetic locus has been identified as associated with arterial 
stiffening. As has been discussed (summarised in Figure 4),  many 
different proteins have been implicated in the mechanisms of increased 
arterial stiffness and increased arterial stiffness has been shown in 
subjects with gene polymorphisms for angiotensin converting enzyme64 
(ACE), angiotensin II type 1 receptor,65 endothelin A and B receptor,66 
collagen I α1,67 fibrillin-1,68 IGF-1,69 α –adducin,70 aldosterone synthase,71 
and MMPs 3 and 9.72,73  
Mitchell et al. suggest that increased pulse pressure has a 
moderate inheritability in the Framingham heart study population. They 
performed a genome wide scan which found some correlation with 
reflective wave amplitude, forward wave amplitude and mean arterial 
pressure. Variance analysis suggested linkage to genetic loci on 
chromosomes 1, 2, 4, 7, 8, 13 and 15. This study found no evidence of 
linkage with previously implicated genetic polymorphisms, which had 
been identified in small diseased study populations, rather than in a 
community-based unselected sample.74 
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Conclusions 
Changes in both the structural and cellular components of the arterial wall 
result in increased arterial stiffness. These changes may reversible or 
irreversible. On a structural level, the majority of these changes are 
irreversible and come about as a result of the change in elastin and 
collagen homoeostasis, largely mediated by MMPs. Changes in the 
cellular control of arterial stiffness is via altered VSMC tone and 
endothelial cell function. Limited evidence has been found for genetic 
causes of arterial stiffness, but given the multifactorial nature of the 
causes of arterial stiffness and thus the multiple different proteins 
involved there are many putative genetic loci. 
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4 
CLINICAL IMPLICATIONS OF ARTERIAL 
STIFFNESS 
Arterial stiffening was just thought to be part of the ageing process, with little clinical 
significance. However it is now clear that whilst arterial stiffness does increase with age, 
accelerated arterial stiffening has a strong relationship with many disease states. 
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Relationship with age 
Qualitative changes in cardiovascular physiology with age have been 
noted for well over 100 years.15,75 However interest in the quantitative 
limits of blood pressure gained favour over the qualitative form with the 
emergence off the cuff sphygmomanometer. Whilst there is now a much 
newer body of research with relevance to vascular ageing, it must be 
regarded with caution. The reasons for this include a lack of an accurate 
animal model to simulate human cardiovascular ageing,76-79 inaccuracy of 
non-invasive investigations, difficulty in discriminating the difference 
between natural ageing and occult disease, controversy over what the 
natural ageing process actually is, difficulty in identification of the reserve 
physiological capability of cardiovascular and other organs, and finally 
errors resulting from cross-sectional studies that may in fact contain only 
super fit survivors rather than subjects more susceptible to the effects of 
ageing who have already fallen by the wayside.80 
Structural and functional arterial changes with increasing age 
Many physicians regard the increasing prevalence of atherosclerosis with 
age as a normal part of arterial ageing. However the process they refer to 
is stenotic and localised and should be regarded as an entity separate 
from arterial ageing, a process which is diffuse across the arterial tree 
and characterised by dilation and increased stiffness.81 Atherosclerosis is 
predominantly a disease of the intima, and has well recognised localised 
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sites of affliction within the arterial tree, where as ageing change has a 
more diffuse pattern and arises in the media. The main effect brought 
about by atherosclerosis is distal ischaemia as a result of the obstructing 
atherosclerotic plaque, with the only dilatory effect being found in the 
distal abdominal aorta. Ageing change causes diffuse arterial wall 
weakness and thus may present with aneurysmal change anywhere in 
the arterial tree. Histological studies in different human ethnic groups both 
prone and not prone to atherosclerosis or hypertension have 
demonstrated that the age-related changes to the human arterial wall do 
involve intimal hyperplasia. However the most significant change is in the 
arterial media.  Here there is a loss of the orderly arrangement of elastin 
fibres which also undergo thinning splitting, fraying and fragmentation. 
There is also an increase in collagen and ground substance.82 These 
changes are not confined to old age, but are progressive throughout life, 
as are the accompanying functional changes.76 On a microscopic level, 
increased amounts of collagen and glycosaminoglycans are found in the 
aortic wall with ageing, together with a decreasing amount of smooth 
muscle and structurally normal elastin.82 
The main functional change with age appears to be progressive stiffening 
of the central aorta with subsequent effect on cardiac function.15,83 
Increased aortic stiffness with age has been found in both western 
populations with a high propensity towards atherosclerosis and other 
populations not prone to atherosclerosis.84-88 It is therefore is believed to 
be a genuine age dependent change. At any particular age there is a 
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wide range of arterial stiffness.89 This finding appears only to hold for the 
aorta and other central elastic arteries, with little evidence being found for 
a change in stiffness with age in the muscular arteries such as the 
brachial, radial or femoral.36, 86, 90 
Relationship with lifestyle and disease 
Arterial stiffness and atherosclerosis 
The association between increased arterial stiffness and atherosclerosis 
is clear91,92 and has been shown in humans,93-95 nonhuman primates96 
and other mammals.97,98 Looking at apolipoprotein E knockout (apoE-KO) 
mice, Wang et al have shown that these mice develop moderate 
atherosclerotic lesions in the aortic arch at four months old. These lesions 
increased significantly in size at the age of 13 months. However aortic 
stiffness, measured invasively, was significantly increased only at thirteen 
months and not at four months in these mice when compared to age-
matched wild type controls. This evidence suggests that atherosclerotic 
lesions develop before arterial stiffness. The exact mechanism by which 
atherosclerotic lesions cause arterial stiffness is not known. The 
mechanism may be a direct result of foam cell accumulation in the intima, 
but secondary responses to inflammation and oxidation provoked by 
foam cells such as elastin degradation, endothelial dysfunction and 
medial thickening must all play a role.99 Young subjects with isolated 
hypercholesterolaemia have normal or increased arterial compliance 
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suggesting that the latter mechanisms are more likely to blame,100 but 
given the evidence that atherosclerosis and arterial stiffening frequently 
coexist and that causative mechanisms appear to be similar, the exact 
relationship remains uncertain. 
Diabetes mellitus and metabolic syndrome 
Many studies have found increased arterial stiffness across all age 
groups in subjects with diabetes and metabolic syndrome. The closest 
correlation has been observed in obese children with metabolic 
syndrome.101 Study populations with metabolic syndrome show increased 
arterial stiffness in proportion with the degree of metabolic 
derangement.102 Increased stiffness is demonstrated in populations with 
decreased glucose tolerance103 and insulin resistance.104 Arterial 
stiffening, therefore, may be present from the beginning of an insulin 
resistant state, and before type 2 diabetes develops. 
Comparing a population of young patients with type 1 diabetes to 
healthy age matched volunteers; acute hyperglycaemia had no effect on 
arterial stiffness in healthy controls but did cause increased stiffness in 
the diabetic group. Interestingly the baseline arterial stiffness in both 
populations was similar, suggesting that the development of arterial 
stiffness in type 1 diabetes is related to exposure to chronic 
hyperglycaemia.105   
The chronic state of hyperglycaemia and hyperinsulinaemia 
stimulates the renin angiotensin aldosterone system (RAAS) and 
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angiotensin type 1 receptor expression in vascular tissue106 thus causing 
wall hypertrophy and fibrosis107 and promotes non-enzymatic glycation of 
proteins with subsequent AGE production. Further stiffening is caused by 
endothelial dysfunction stimulated by high LDL, free fatty acids,108 
endothelin-1, decreased levels of adiponectin109 and natriuretic 
peptides.110 
Hypercholesterolaemia 
Animal studies have shown that hypercholesterolemia caused by 
cholesterol rich diet provokes an initial decrease in arterial stiffness, 
followed an increase in stiffness over time which is then reversed by 
lowering serum cholesterol.96,111,112 
Data from current research studies suggests a positive correlation 
between increased arterial stiffness and familial hypercholesterolemia. 
However this evidence is not conclusive as the studies have used a 
number of different methods of measuring arterial stiffness and several 
have small sample sizes. Familial hypercholesterolemia is characterised 
by high plasma levels of low-density dietary protein, and the prevalence 
of premature and severe coronary disease. The available data has 
produced conflicting results in both children and adults. Lehman et al 
reported increased aortic distensibility in children with familial 
hypercholesterolaemia but decreased aortic distensibility in adults.100 
However Virkola et al113 and Aggoun et al114 both found reduced carotid 
distensibility in children. Pitsavos et al report decreased aortic 
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distensibility in adults,115 and Giannattasio et al report the same when 
looking at radial artery compliance.116 In contrast, Toikka et al, looking at 
carotid and aortic distensibility, found no change in arterial stiffness in a 
case-control study.117 
The evidence for an association between raised lipid sub-fractions 
and increased arterial stiffness in the general population is conflicting, 
and has been summarised as shown in Table 2. As can be seen, whilst a 
number of the studies demonstrate a positive correlation between HDL-
cholesterol and arterial stiffness,118-122 and a few demonstrate a negative 
correlation with LDL cholesterol,121,123,124 there are also many studies that 
demonstrate no conclusive relationship.125-130 
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Table 2: Summary of relationship between arterial stiffness and dyslipidaemia 
Reference Population Measures Main findings 
Taquet125 429 healthy women aortic PWV no independent relationship with 
cholesterol 
 
Giral118 105 hypercholesterolaemic men aortic PWV independently positive association 
with HDL3 cholesterol 
 
Pirro126 60 hypercholesterolaemics, 25 
controls 
aortic PWV independent negative correlation 
with LDL cholesterol, disappeared 
after correction for CRP and waist 
circumference 
 
Lebrun127 385 post-menopausal women aortic PWV positive relationship with 
triglycerides, inverse with HDL 
cholesterol 
 
Czernichow128 917 middle-aged subjects aortic PWV no independent association with 
HDL cholesterol 
Wilkinson119 68 hypercholesterolaemics, 68 
matched controls 
augmentation 
index 
augmentation index higher in the 
hypercholesterolaemic subjects 
and a positive relationship with 
LDL cholesterol 
 
Alagona129 
  
18 low HDL cholesterol 
subjects,18 matched controls 
augmentation 
index 
no difference between groups 
Dart130 868 hypertensives >65yrs augmentation 
index; SAC 
no relationship with total or HDL 
cholesterol 
Dart120 30 hypercholesterolaemics, 24 
controls 
aortic distensibility 
(β index) 
 
cholesterol positively related to β 
index 
Hopkins121 38 healthy adults aortic distensibility inverse correlation with total and 
LDL cholesterol, and positive 
correlation with HDL cholesterol 
 
Toikka117 25 healthy men aortic and carotid 
compliance 
carotid but not aortic compliance 
associated with low HDL: total 
cholesterol ratio; oxidized LDL 
correlated with carotid compliance 
 
Urbina131 516 random subjects carotid elastic 
modulus 
 
positive independent association 
with triglycerides only 
Giannattasio122 10 controls, 10 hypertensives, 
10 hypercholesterolaemics, 10 
mixed 
 
radial artery 
distensibility 
reduced distensibility in both 
hypercholesterolaemic groups 
 
Cameron123 20 patients with CAD, 20 
controls 
SAC inverse association with LDL 
cholesterol 
 
Le124 223 subjects with CAD risk 
factors 
SAC inverse correlation with 
triglycerides and non-HDL 
cholesterol 
Legend: PWV=pulse wave velocity; HDL=high density lipoprotein; LDL=low density lipoprotein; 
SAC=systemic arterial compliance; CAD=coronary artery disease.  (after Wilkinson)132 
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Peripheral arterial disease 
Peripheral arterial disease (PAD) describes a degenerative arteriopathy 
which predominantly affects the distal aorta and vessels supplying the 
lower limbs. It is characterised by the formation of atherosclerotic 
plaques, with a varying degree of in situ thrombosis. In addition, fibrosis 
and calcification of the tunica media is often present. The major symptom 
of PAD is intermittent claudication which is defined as pain and weakness 
in the affected limb on exercise, relieved by rest. This symptom, however 
is absent in most subjects with PAD.133 
The ankle brachial pressure index (ABPI) is a useful non-invasive 
screening tool to look for the presence of PAD in subjects. It is measured 
using a blood pressure cuff and a hand held Doppler (see Figure 5). In 
this way the ratio of systolic blood pressure (SBP) at the brachial artery is 
compared to the SBP in the arteries at the ankle. In a healthy subject, the 
ABPI is greater or equal to 1.0. It may be greater than 1.0 due to the large 
amount of reflected pressure waves from the toes merging with the 
forwards systolic pressure wave only a short distance away at the ankle.  
In disease, as the arterial lumen narrows, SBP drops distal to the 
obstruction, and thus the ABPI is found to be less than 1.0.  A ratio of less 
than 0.9 is considered to be abnormal, demonstrating either systolic 
hypertension or decreased lower limb perfusion. This ratio has been 
shown to be a reliable predictor of PAD134 and also coronary artery 
disease (CAD) and stroke.135 More recently, high ABPI greater than 1.4 
have been shown to be a positive predictor for all cause and 
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cardiovascular mortality, as this is an indication of much increased arterial 
rigidity.136 
 
Figure 5: Measurement of the ankle brachial pressure index 
 
Legend: After Wolfe137 
 
Systemic changes in PAD 
Systolic and diastolic blood pressure has consistently been found  to be 
higher in subjects with PAD than in aged-matched controls, when blood 
pressure is determined non-invasively.138 This may be due to the 
presence of atheroma or hypertrophy of the tunica media. It results in 
inappropriately elevated pressures when calf pressures are compared 
with intra-arterial measurements.139-141 In particular, in the elderly, it 
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appears as though non-invasive measurement overestimates diastolic 
blood pressure (DBP) compared to SBP.142 Intra-arterial studies of 
brachial artery pressure in hospitalised patients with PAD, compared with 
age and sex matched controls, suggest that DBP is relatively unchanged 
compared with SBP in which a sustained and significant rise was found. 
This finding was maintained even when subjects with PAD were 
compared with normal subjects with the same mean arterial pressure 
(MAP).143,144 It is likely that this change in pulse pressure (PP) in the 
brachial artery is also found in the aorta, as the age-related increase in 
PP centrally is probably greater than that found peripherally.145 Given that 
subjects with PAD have a relatively normal cardiac output and systemic 
vascular resistance.143,144 The observed change in PP appears to be 
mainly due to changes in arterial stiffness and wave reflection. In vitro 
studies have demonstrated that reduced large arterial elasticity can cause 
an elevated SBP whilst leaving DBP unchanged or perhaps even 
lowered, as found in subjects with PAD.146,147 
It is likely that the increased arterial stiffness observed in patients 
with PAD affects the whole arterial tree. This observation is made on the 
basis of increased PWV found in subjects with PAD when compared to 
controls with similar MAP,148,149 as well as increased femoral and carotid 
arterial stiffness in subjects with PAD.150,151 The other important factor to 
consider is wave reflection. In healthy subjects, the distal abdominal aorta 
is recognised as an important site for wave reflection.145,146 This site may 
take on increased importance in subjects with PAD, as the smaller 
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luminal diameter and increased arterial stiffness found in an 
atherosclerotic distal aorta would cause the reflected pressure waves to 
travel more quickly, and thus the forwards and backwards moving 
pressure waves would superimpose during systole causing an increase in 
SBP. There is limited evidence to support this theory in subjects who had 
undergone traumatic amputation of the lower limbs and who later in life 
demonstrate a high incidence of systolic hypertension.152 
Role of endothelial dysfunction in PAD 
An increasing body of evidence exists that suggests that increased 
arterial stiffness with PAD is due to more than just structural arterial wall 
change.  This evidence of endothelial dysfunction is demonstrated by 
impaired flow mediated dilatation in the brachial artery,153 elevated 
plasma concentrations of markers of endothelial dysfunction,154 and a 
higher increase in brachial SBP after isotonic saline infusion than in 
matched control populations.155 In contrast arterial stiffness was shown to 
be improved in subjects with PAD after exercise,156 L-arginine 
administration,157 autologous bone marrow transfusion,158 nitrate 
administration,146,152 and Ramipril, an angiotensin converting enzyme 
inhibitor (ACE-I).159 
Effect of arterial stiffness on haemodynamics in PAD 
There is a strong positive correlation between systemic blood pressure 
and calf blood flow at rest in subjects with PAD, a relationship not found 
in healthy subjects,160 with studies demonstrating that calf blood flow in 
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subjects with PAD remains normal at rest.161,162 These findings suggest 
that there may be regulation of systemic blood pressure in order to 
promote lower limb perfusion in the presence of PAD. 
PP also has a positive correlation with calf blood flow at rest, and 
this relationship is maintained for PP during exercise, unlike MAP. As a 
result, the higher PP is at rest, the greater is the reduction in walking 
distance.160 This suggests that increases in baseline arterial stiffness 
have an important role in the symptomatic severity of subjects with 
intermittent claudication.133 
Cerebrovascular disease 
Cross-sectional studies demonstrate good correlation between markers 
of arterial stiffness and risk factors for stroke.163,164 Increased aortic 
stiffness has been demonstrated in subjects  with cerebrovascular 
disease (CVD) who have suffered a cerebrovascular accident (CVA).95 
Longitudinal studies have demonstrated that increased arterial stiffness is 
an independent risk factor for cerebrovascular events in a population with 
primary hypertension165 and a separate population of healthy elderly 
subjects.166 
Coronary artery disease 
As with other clinical manifestations of atherosclerosis, the available 
evidence suggests that arterial stiffness may be a cause of CAD, a 
consequence and also an exacerbation.167 There is good evidence that 
arterial stiffness is associated with CAD,94,168-173 myocardial 
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ischaemia167,174 and increased mortality from heart disease.175 Positive 
correlation between pulse pressure and CAD has also been 
demonstrated in a longitudinal study of a population of subjects with 
hypertension.175 The mechanisms by which arterial stiffness may cause 
CAD are not clear, but increased arterial stiffness is likely to cause 
systolic hypertension, which in turn would cause increased cardiac 
afterload and left ventricular hypertrophy. Given that most cardiac 
perfusion occurs during diastole, decreased diastolic pressure would 
reduce this and thus, in conjunction with an increased pulse pressure, 
demand would increase and supply would diminish.176 Animal studies 
have demonstrated that cardiac energy consumption and pulse pressure 
increase when cardiac ejection is into a stiffer aortic conduit.177 
Furthermore cardiac perfusion in a heart with a deliberately created 
coronary artery stenosis is much worse when ejection is into a stiffer 
aorta.178 Leung et al have provided some corroborative clinical evidence 
for these findings by demonstrating that both coronary blood flow and 
subsequent improvement in blood flow was lower in subjects with higher 
aortic stiffness as measured by PWV when undergoing percutaneous 
coronary reperfusion.174 
Renal disease  
Access to dialysis in end stage renal disease (ESRD) is no longer 
restricted. As a result, patients with ESRD are living longer and are dying 
from cardiovascular complications of renal failure rather than the disease 
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itself. The mortality in this population is in the order of 10% per annum,179 
and arterial stiffening is a strong independent predictor of this.180 The 
mechanisms implicated for the observed accelerated arterial 
degeneration are: 
 increased IMT secondary to increased wall stress from 
hypertension,30  
 increased ECM collagen content and VSMC proliferation,30  
 decreased collagen elasticity due to AGE formation and reaction 
with methylglyoxal and other reactive carbonyl compounds which 
are found in increased amounts in uraemia181 and  
 calcification of the media.182   
In subjects with a renal transplant, increased stiffness is strongly 
correlated with the length of time that these subjects received 
haemodialysis.183 
Conclusions 
Whilst it is widely accepted that arterial stiffness increases with age, there 
is no reliable animal model available for research. Most studies are cross-
sectional in design and may therefore only include fit survivors by default. 
There is now a large body of evidence to support a relationship between 
increased arterial stiffness, cardiovascular disease and disease states 
known to promote cardiovascular disease. In particular subjects with PAD 
(diagnosed by reduced ABPI) have been shown to have increased 
arterial stiffness and be at high risk of future cardiovascular events.
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                                                          5 
MODULATION OF ARTERIAL STIFFNESS 
Given the association of increased arterial stiffness with increased prevalence of 
cardiovascular disease, the assumption has been made that decreased arterial stiffness 
is a worthwhile therapeutic goal. Currently there is little published evidence to support 
this. Methods to decrease arterial stiffness are based on modifications of diet, lifestyle 
and the addition of pharmacological agents, usually anti-hypertensives or statins. These 
methods can be successful in reducing arterial stiffness, but evidence that this effect 
translates into clinical benefit is lacking. 
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Introduction 
Perhaps unsurprisingly, most methods of reducing arterial stiffness have 
been found or have been investigated as a by product of treating 
cardiovascular disease and its risk factors. As will be seen, these 
methods can be categorised into modification of lifestyle or addition of a 
pharmacological agent. 
Based on the evidence that subjects with many chronic diseases 
have increased arterial stiffness when compared to a healthy control 
population, and that subjects such as athletes or the physically active 
elderly have decreased arterial stiffness when compared to a normally 
active control population,184,185 the presumption has been made that 
reducing arterial stiffness is a worthwhile therapeutic goal. However there 
is little evidence to support this, as randomised clinical trials with both the 
aim of decreasing arterial stiffness and the appropriate outcome 
measures (such as morbidity or mortality) are yet to be reported in the 
literature. The only study of this sort revealed by literature search was 
carried out in patients with end-stage renal disease, and thus is not 
applicable to the general population.186 This paucity of research is 
perhaps not surprising given not only the controversy surrounding 
measurement of arterial stiffness but also the lack of consensus on 
desired therapeutic goal in terms of degree of reduction of arterial 
stiffness. If this becomes clear, together with a clearer picture of the 
contribution to cardiovascular risk that increased arterial stiffness makes, 
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then targeted therapy may become part of best medical therapy to reduce 
cardiovascular risk on the basis of future urgently required clinical trials. 
Modification of lifestyle 
The most successful lifestyle modification appears to be endurance 
exercise. In healthy individuals, without any evidence of cardiovascular 
disease but who have increased arterial stiffness secondary to ageing, 
the increase in arterial stiffness was found to be less in those who 
participated in regular exercise.184 It was also found that a three-month 
programme of aerobic training decreased levels of carotid artery stiffness 
in middle-aged men with known arterial stiffness to similar levels of 
arterial stiffness in endurance trained men of the same age.187 These 
benefits appeared to continue after exercise training has ceased,188 and 
appear to be secondary to mechanical stimulation of the endothelium 
resulting in enhanced nitric oxide production together with decreased 
release of neurohumoral vasoconstrictors and efferent sympathetic 
tone.189 However no decrease in arterial stiffness was found in trials of 
aerobic exercise in subjects with systolic hypertension190 or subjects who 
were very elderly,191 Anaerobic training, such as weightlifting, has been 
shown to increase arterial stiffness.192 Weight loss in healthy men has 
been shown to reduce arterial stiffness but this finding was not 
maintained when adjusted for decrease in blood pressure.193 
Reduction of salt intake decreases arterial stiffness in the short 
and long-term, independent of the effect on blood pressure.194,195  Salt 
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exposure induces structural changes in the vascular wall that have been 
identified in rats fed on a high salt diet.196 This may explain the 
accelerated age related arterial stiffening found in subjects who have a 
high salt intake.88  
Alcohol consumption similarly lowers arterial stiffness independent 
of blood pressure,197,198 but this relationship is weaker when adjusted for 
HDL cholesterol. HDL cholesterol promotes reverse cholesterol transport 
and is increased with exposure to alcohol, thus suggesting that the effect 
that alcohol exposure has on arterial stiffening is mediated by increased 
levels of HDL cholesterol.179 Moderate alcohol exposure in healthy males 
has additionally been found to increase cellular cholesterol efflux.199 
Other dietary additions have also been shown to decrease arterial 
stiffness, notably isoflavones,200,201 fish oil,202 garlic,203 and flax seed 
oil.204 
Pharmacological modulation 
As previously discussed, most pharmacological agents that have been 
shown to decrease arterial stiffness are anti-hypertensives, which cause 
this effect indirectly as a result of reduction in MAP or PP. Some 
antihypertensive appear to have little or no effect (diuretics, B-blockers, 
dihydralazine). This section focuses on medications which appear to have 
an effect on the structure and function of the arterial wall, and (with the 
exception of nitrates) which appear to decrease arterial stiffness 
independent of effect on blood pressure. 
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Statins 
Statin is the common term for 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase inhibitors. This class of drug has progressed from 
use merely in cholesterol lowering therapy to being viewed as the main 
anti-atherosclerotic agent with pleiotropic effects well beyond the 
management of lipoproteins. 
As the name implies, the main action of statins are to block the 
rate-limiting step in cholesterol synthesis by inhibiting the enzyme HMG-
CoA reductase. Thus at therapeutic levels, both serum total and LDL 
cholesterol levels are reduced. The evidence is clear that this is beneficial 
in terms of both primary and secondary prevention of cardiovascular 
events in subjects with high hypercholesterolaemia.205 However the 
preventative effect of statins has also been shown in subjects without 
hypercholesterolaemia,206 thus suggesting that statins may beneficial in 
other ways. These mechanisms are summarised in Table 3. 
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Table 3: Summary of the pleiotropic effects of Statins 
effect specific details 
 
 
anti-thrombotic  
 
reduction in PAI-1  
increase in t-PA 
increase in NOS expression and activity  
reduction in tissue factor expression  
reduction in fibrinogen  
decreased platelet aggregation 
increase in thrombomodulin 
 
endothelial cell biology enhanced eNOS expression and activity 
reduction in genes for leucocyte adhesion 
anti-inflammatory signals 
reduction in endothelial inability 
increase endothelial growth 
increase in endothelial progenitor 
cells/angiogenesis 
reduction in pre-pro-ET-1 expression 
 
vascular smooth muscle 
cells 
reduction in VSMC growth and migration 
decrease in expression of AT1 receptor in 
response to an injurious stimuli 
 
miscellaneous  Reduction in generation of oxidant species 
increase in gene expression of antioxidants 
decrease in fibroblast growth and collagen 
formation 
inhibition of LDL oxidation and ox-LDL 
uptake 
inhibition of mitogen-stimulated T-and B-
lymphocyte proliferation 
inhibition of expression of class two MHC 
blockade of the effects of angiotensin II 
inhibitor of natural killer cell cytotoxicity 
stimulation of bone formation 
 
Legend: PAI-1=plasminogen activator inhibitor type 1; t-PA=tissue plasminogen 
activator type 1; NOS=nitric oxide synthase; eNOS=endothelial nitric oxide synthase; 
pre-pro-ET-1=pre-pro-endothelin-1; VSMC=vascular smooth muscle cell; 
AT1=angiotensin type 1; LDL=low density lipoprotein; ox-LDL= oxidised low density 
lipoprotein; MHC=major histocompatibility complex. (after Sinha)207 
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There are few studies looking at the direct effect of statins on 
arterial stiffness. These are summarised in Table 4.The data is difficult to 
interpret due to the use of different statins in separate studies. In addition 
the method used to measure arterial stiffness varies from study to study. 
The overriding implication from this research appears to be that long term 
use of atorvastatin and fluvastatin decreases arterial stiffness in a variety 
of study populations with or without hypertension, and that this finding is 
independent of effect on systemic blood pressure.208-210 Interestingly the 
short term results of Statin exposure suggest a transient rise in arterial 
stiffness, hypothesised to be due to the initial reduction in lipid vascular 
content.211  
The most important mechanisms to explain these findings would 
appear to be increased activity of endothelial nitric oxide synthase and 
thus increased production of nitric oxide in vascular endothelial cells.212 
As previously discussed NO is a potent vasodilator and platelet inhibitor.  
The direct effect of HMG-CoA reductase inhibition is to prevent the 
conversion of HMG CoA into mevalonate. Mevalonate is the precursor of 
cholesterol and also isoprenoids which are involved in the lipid 
modification of regulatory proteins.213 Thus down-regulation of 
isoprenoids may alter cell signalling, proliferation and intracellular 
trafficking.  In addition statins may have immunomodulatory effects,214 
and may promote inhibition of LOX-1, a receptor for oxidised LDL that is 
known to be up regulated in atherosclerotic lesions, and which promotes 
the release of matrix metalloproteineases.215 Decreased quantities of 
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plasminogen activator inhibitor type 1 (PAI-1) and increased quantities of 
tissue plasminogen activator (t-PA) have been noted in endothelial cells 
treated with statins. T-PA is important in the control of tissue remodelling, 
fibrinolysis and atherosclerosis and is inhibited by PAI-1.216,217 
 
Table 4: Summary of effect of statins on arterial stiffness 
Author Study population Study 
drug(s) 
stiffness 
measurement 
Result 
 
Ichihara208 
 
85 subjects with 
hyperlipidaemia and 
hypertension 
 
pravastatin 
fluvastatin 
simvastatin 
lower than 
normal 
therapeutic 
doses 
 
aortic PWV 
 
PWV decreased 
transiently in 
simvastatin 
group, 
significantly in 
fluvastain group, 
not with 
pravastatin after 
follow up for 1 
year 
Raison211 23 subjects with 
hypertension and 
hypercholesterolaemia 
atorvastatin 
or placebo 
aortic PWV no change in BP 
but increased 
PWV after 3 
months in 
atorvastatin 
group 
Kontopoulos209 36 subjects with 
hypercholesterolaemia 
but no hypertension or 
diabetes. 18 with CAD 
and 18 without CAD 
atorvastatin transthoracic 
echocardiography 
aortic stiffness 
significantly 
reduced after 2 
years 
Ferrier210 22 subjects, 
normolipidaemic with 
isolated systolic 
hypertension 
atorvastatin carotid 
applanation 
tonometry and 
Doppler 
velocimetry of the 
ascending aorta 
systemic arterial 
compliance 
significantly 
increased in 
subjects taking 
atorvastatin after 
3 months 
 
48 
 
Nitrates 
Several trials have studied the effect of nitrates on arterial stiffness. The 
main effect appears to be a reduction in pulse pressure brought about by 
a decrease in SBP but not in DPB. Duchier et al and Starmans-Kool et al 
looked at the effect of chronic isosorbide dinitrate (ISDN) administration in 
double-blind randomised placebo controlled studies.218,219 They both 
found a decrease in SBP with ISDN when compared to placebo, but no 
decrease in DBP. This suggests that the main effect of nitrates is on 
smooth muscle tone in the larger muscular arteries as opposed to an 
effect on the smaller high resistance vessels which would be manifest by 
a decrease in DBP. However the long term effect of nitrate administration 
is hampered by the development of tolerance. 
Sinitrodil (an NO donor) administration, caused a greater increase 
in brachial artery compliance but a lesser decrease in total peripheral 
resistance than ISDN in healthy subjects suggesting that it may be 
possible to develop more selective drugs that act on a large arterial 
stiffness.220 
Renin angiotensin aldosterone system 
The main drug class acting on the renin angiotensin aldosterone system 
(RAAS) are Angiotensin Converting Enzyme Inhibitors (ACE-Is). As well 
as being recognised as effective anti-hypertensive agents, they are of 
great interest in the treatment of atherosclerosis as they have been 
shown to protect against secondary coronary events in subjects with 
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cardiovascular disease.221 This effect was found to be independent of 
blood pressure reduction, suggesting that this may be due to vessel wall 
remodelling. Animal models have demonstrated that activation of the 
RAS causes expansion of the extra cellular matrix (ECM) and 
fibrosis.196,222 This fibrosis is characterised by the presence of 
inflammatory cells and activation of tissue response to injury pathways.223 
The remodelling effect of ACE-Is in mouse, pig, rabbit and monkey 
models of atherosclerotic disease has been demonstrated showing 
reduction in size of atherosclerotic lesions.224-229 In addition improvement 
of endothelial dysfunction was shown in subjects with coronary artery 
disease after ACE-I administration.230,231  
Aldosterone antagonists 
Rat model experiments have suggested that aldosterone infusion causes 
increased rigidity of the aortic wall in the presence of a high salt diet, a 
phenomenon that was reversed when epleronone, an aldosterone 
antagonist, was administered.232 Using immunohistochemical staining, 
Lombes et al found a higher density of mineralcorticoid receptors in the 
proximal aorta with the density decreasing with arterial diameter.233 This 
provides a potential explanation for the way in which aldosterone agonists 
reduce arterial stiffness. However despite the fact that increased plasma 
aldosterone  and increased arterial stiffness has been found in untreated 
hypertensives,234 a study treating hypertensive subjects with 
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spironolactone did not demonstrate any reduction in arterial stiffness, 
perhaps because subjects were only given the drug for two weeks.235 
Conclusions 
 Modulation of arterial stiffness has been shown to be successfully 
managed via changes in lifestyle, in terms of diet and exercise. Attention 
to pharmacological modulation has focused around antihypertensive 
drugs and statins. Certain statins (atorvastatin and fluvastatin) have been 
shown to decrease arterial stiffness with chronic use, perhaps as a result 
of their pleiotropic effects. ACE-Is have also been shown to decrease 
arterial stiffness independently of reduction in blood pressure. There is 
limited evidence that this may be due to vessel wall remodelling. Other 
anti-hypertensives probably manifest a reduction in arterial stiffness as a 
result of decrease in blood pressure. 
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6 
OVERVIEW OF A TISSUE DOPPLER IMAGING 
BASED METHOD TO CALCULATE INDICES OF 
ARTERIAL STIFFNESS  
The TDI based system uses Doppler scanning and dedicated software to identify and 
capture information about arterial wall motion. This is performed by capturing cineloops 
of 5 seconds duration and then transferring then offline to a personal computer for 
analysis by accompanying software. This allows calculation of the arterial distension 
waveform. Together with measurement of intima-media thickness and brachial blood 
pressure it is then possible to calculate indices of arterial stiffness. 
52 
 
Introduction 
The basic parameters that an ultrasound system can measure are 
distance, time and velocity. All other parameters are inferred and 
historically very time consuming to calculate, as well as having quality 
control issues in terms of inter and intra operator reproducibility. The main 
advantage of ultrasound when compared to other imaging modalities 
remains that it is the only method able to generate real-time images 
without the use of ionising radiation.  
The tissue Doppler Imaging (TDI) system developed by Philips 
ATL applies broadband Doppler processing and dedicated scanning 
sequences which are designed to accommodate the low tissue motion 
velocity of arterial walls (max 2 cms-1) and also the high frame rate (40 
Hz) required to accurately sample arterial wall motion (AWM) over the 
cardiac cycle. It has been shown using a moving platform phantom that 
the TDI technique has a resolvable displacement of 22 µm and a 
measurement accuracy of 8% using a physiological wall motion with a 
peak displacement of 689 µm.236 
The known limitations to this system are that the software will not 
accurately identify the arterial walls in the following circumstances: 
 
 the insonated vessel has a lumen of less than 3 mm,  
 the vessel has a branch in the area to be interrogated, and  
 vessel is more than 7 cm below the skin surface.237  
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This last limitation is due to the fact that TDI software will only run using 
data collected from an L 12/5 linear array of the HDI 5000 ultrasound 
imaging system (Philips Medical Systems, Bothell, WA, USA), which has 
a maximum tissue penetration of up to 7cm. 
A number of other factors have been found to affect AWM 
measurement precision when investigated using an arterial phantom; 
vessel depth (variation 7±3%), misalignment of beam-vessel angle from 
90° (22±3%), degree of scan plane coincidence with the central vessel 
axis (34±2%), and transducer pressure on the insonated vessel   
(20±3%).238 
Acquisition of scan data 
The common carotid artery (CCA) approximately 3 cm proximal to the 
carotid bulb, was imaged longitudinally using the L12/5 linear array of an 
HDI 5000 ultrasound imaging system (Philips Medical Systems, Bothell, 
USA). Scan-plane alignment was performed using B-mode imaging to 
ensure that echoes from the intima-media layers were clearly visible. 
Tissue Doppler imaging (TDI) was enabled and real-time images were 
collected of a 2 cm segment of the CCA over at least three cardiac 
cycles. This was saved to disc as a cineloop and transferred off-line for 
analysis via an Ethernet connection to a laptop computer. 
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Offline analysis of arterial distension waveform data 
After transfer of the raw cineloop to the PC, a commercial software 
analysis package (HDI-Lab, Philips Medical Systems, Bothell, WA, USA) 
was used to obtain wall distension waveforms from the TDI data (Figure 
6). 
 
Figure 6: Screenshot of the AWM software used to analyse captured 
cineloops. 
 
Legend: 1 moveable box this can be changed in size in order to direct the program to 
interrogate the region of interest (ROI); 2 colour information that indicates direction of 
movement of the arterial wall over time; 3 ADW trace shown graphically for entire length 
of cineloop; 4 detailed graph of ADW for each cardiac cycle. The thick grey line is made 
up of a plot of all 50 lines of information. As movement is so homogeneous in this 
sample, it appears as one thick grey line. The white line represents the mean of all 50 
grey lines (MADC). 
 
 
The core feature of this technique is that TDI data provides 
information on wall velocity as a function of time. Wall motion is then 
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calculated by integration of velocity with respect to time. The system 
interrogates wall motion throughout all recorded cardiac cycles in the 
cineloop. This interrogation is performed for each scan-line of the TDI 
image and is recorded as change from baseline (in micrometers), thus 
providing some 50 measurements of the distension-time waveform over a 
2 cm length of artery (see figure 7). The arterial diameter change (ADC) 
for each line can be pooled to allow calculation of the mean arterial 
diameter change (MADC) for use in calculation of indices of arterial 
stiffness. Alternatively the ADC for each scan line can be plotted to 
provide the arterial distension waveform (ADW, Figure 8). 
 
Figure 7: A graphical illustration of ADC and MADC.  
 
Legend: The system records wall motion of the artery as change from baseline (yellow 
arrowed lines in figure) over the cardiac cycle along 50 scan lines (blue lines in figure). 
This can then be plotted as a distension waveform (as demonstrated in Figure 8) or 
pooled to calculate mean arterial diameter change to be used to calculate indices of 
arterial stiffness. 
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Figure 8: A graphical representation of arterial distension waveform  
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Legend: Dilations = how far in microns arterial wall moved apart during cardiac cycle; 
Scan line number= virtual line down which software calculated arterial wall dilatation (48 
line in total); Time = total length in time of scan and scale over which arterial dilatation 
occurred. This data was captured over 4 cardiac cycles from a segment of common 
carotid artery measuring approximately 2cm. 
 
This data can then be exported as a Microsoft Excel file from the 
software, thus allowing numerical interpretation of the waveform. Each 
Excel file from each scan contains approximately 20000 points of 
information. These data were summarised to provide the following 
information. The MADC was calculated from all lines in all cardiac cycles 
in which the ADC was measured by obtaining the maximum excursion for 
each line and then taking the mean of all these values. This process was 
automated using a Macro in Microsoft Excel to enable efficient extraction 
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of the required value from the raw data and has been reproduced in 
Appendix 2. 
Calculation of IMT and arterial diameter 
IMT and arterial diameter was calculated from the same segment of CCA 
in the same cineloop transferred to the personal computer using HDI Lab, 
using commercial software from Philips ATL, (IMT plug-in, LDOT plug in 
HDI-Lab, Philips Medical Systems, Bothell, WA, USA) that interrogates all 
digital frames within the cineloop in order to calculate mean IMT and 
mean diameter via B. mode ultrasound. HDILab uses an edge detection 
algorithm in order to identify the start and finish of both near and far wall 
intima media complex in a defined region of interest within the cineloop 
(Figure 9). This data is then presented as mean IMT for the near and far 
wall of the artery. Mean IMT for the far wall in all frames across all cardiac 
cycles captured in the cineloop was used to calculate indices, in view of 
published advice that IMT changes across the cardiac cycle and that 
measurement of IMT in the far wall as opposed to the near wall is more 
accurate.239 
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Figure 9: A screenshot of HDI Lab calculating IMT and diameter for both 
the near and far arterial wall. 
 
Legend: green box = defined area of interest. Horizontal yellow line =near wall 
adventitia-media interface; blue line = near wall intima media interface; purple line = 
near wall intima lumen interface; red line = lumen intima interface; horizontal green line 
= far wall media adventitia interface. 
 
Blood pressure measurement 
Three blood pressure measurements in the right brachial artery using a 
Critikon automated blood pressure manometer (GE Healthcare, Bucks, 
UK) were recorded whilst the patient remained supine, at the same time 
as AWM data was collected. One measurement was taken before scan 
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acquisition; one whilst the data were transferred off-line for analysis and 
one after data capture was completed. Whilst these blood pressure 
measurements were taken at the same sitting as AWM data was 
captured, the measurements were not synchronous. The mean change in 
blood pressure (∆p) of the three measurements was used to calculate 
indices of arterial stiffness as appropriate. 
 
Calculation of ankle brachial pressure indices  
In certain parts of the study, ABPIs were recorded using the following 
method. A manual sphygmomanometer was placed around the mid calf 
of each leg. The posterior tibial, anterior tibial and perforating peroneal 
arteries were insonated with a hand held Doppler (Mini Dopplex®, 
Huntleigh Diagnostics, Cardiff, UK).The cuff was inflated until the signal in 
the insonated artery disappeared, indicating occlusion. The highest 
pressure at the ankle recorded in any artery on cuff deflation was divided 
by the highest systolic brachial pressure to give the ABPI for each leg. 
 
Conclusions 
The entire system used to collect the data required to calculate indices of 
arterial stiffness using the distension waveform from the common carotid 
artery and blood pressure from the brachial artery is summarised in 
Figure 10. 
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Figure 10: Schematic summary of entire system used to collect data 
required to calculate indices of arterial stiffness 
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7 
INVESTIGATING AND CONTROLLING SCAN 
VARIABILITY 
 The TDI based system to measure arterial stiffness has only been used in a lab 
based setting. The aim of this study was to use the system to capture data from healthy 
volunteers in order to develop a basic methodology for validation in a reproducibility 
study. 
 100 subjects who were either patients or staff at Heartlands Hospital were 
recruited into the study. Both CCAs in each subject were insonated and cineloops 
collected from them, together with three blood pressure readings from the right brachial 
artery. These cineloops were then analysed offline to provide the ADW and 
subsequently the MADC.  
 Initial data capture was unreliable. Repeated scan acquisitions from the same 
subject demonstrated that reliable data capture was achieved if correct scan plane 
alignment was maintained so that the intima-media complex was uniform and fully 
visible throughout the whole of the ROI within the cineloop. Analysis of the between 
cycle coefficient of variation, together with evidence from a phantom model suggested 
that the following requirements were necessary for reliable data capture; diameter 
greater than 3 mm; no side branches; ensure subject is rested and comfortable on 
couch prior to scan acquisition for 5 minutes; exclude subjects with breathing difficulties; 
exclude subjects with cardiac arrhythmias; ensure scan plane alignment in ROI. 
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Introduction 
The TDI system has never been used on a large number of patients, nor 
clinically validated. A research group from the Department of Medical 
Physics at the University of Edinburgh has extensively bench tested this 
system and found that it is a reliable technique that accurately measures 
arterial wall displacement when investigated using an arterial phantom.238 
However, it is not fully known what the limitations of the TDI system are 
when attempting to calculate indices of arterial stiffness in human 
subjects. Initially therefore, a variability study was carried out to 
investigate between cardiac cycle variability of measurement in cineloops 
captured from the CCAs of subjects in order to develop a reliable method 
for data collection. 
 The hypothesis was that the TDI system should allow collection of 
AWM data from the carotid arteries of human subjects with acceptable 
and low variability. 
Method 
Study design 
All subjects recruited into the study provided fully informed written 
consent. Ethical approval was granted by Birmingham East District 
Research and Ethics Committee. All subjects completed a questionnaire 
regarding past medical history and drug evidence. 
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100 subjects who were either patients or staff at Heartlands 
Hospital were recruited into the study. Both CCAs in each subject were 
insonated and cineloops collected from them, together with three blood 
pressure readings from the right brachial artery. These cineloops were 
then analysed offline to provide the ADW and subsequently the MADC.  
Calculation of variability  
The between cycle coefficient of variation (BCCOV) of the MADC for 
each cardiac cycle was calculated as it was believed that problems with 
scan acquisition would be highlighted by disparity in the ADC between 
each cardiac cycle within a cineloop. The BCCOV was defined as the 
standard deviation divided by the mean times 100 for the MADCs of each 
cardiac cycle within each cineloop. All acquired scans were then 
inspected manually with attention paid to those scans with high or low 
BCCOV. 
Results 
200 hundred scans were collected from 100 subjects. After inspection 
and analysis, the following errors were found. 
Misidentification of the arterial walls 
Initial inspection demonstrated that in 70 cineloops (out of 200), the AWM 
system had miss-identified the arterial wall (usually the far wall). It was 
thought that this may relate to greyscale levels within the cineloop as it 
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was recorded or to artefact within the lumen of the insonated artery 
(Figure 11).  
 
Figure 11: Scan acquisition of miss-identification of arterial walls by 
AWM system  
 
Legend: poor scan plane alignment caused part of the side wall of the artery to be miss-
identified as the far wall, highlighted within the red circle. 
 
However repeated scan acquisitions from the same subject 
demonstrated that these issues were resolved if correct scan plane 
alignment was achieved so that the intima-media complex was uniform 
and fully visible throughout the whole of the ROI within the cineloop. The 
AWM System was then able to consistently identify the arterial walls 
correctly and analyse the cineloop to provide a complete data set of the 
ADW across all cardiac cycles, as is demonstrated in Figure 12. 
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Figure 12: Screenshot of successful scan plane alignment during 
cineloop capture. 
 
Legend: The Intima-media complex is uniform in the ROI, suggesting ideal scan plane 
alignment bisecting the diameter of the artery and resulting in correct identification of 
both arterial walls. 
Extra Arterial Movement 
Extra arterial movement was noted when the cineloops were viewed off 
line in a number of scans. Two extreme examples of this are described. 
In Figure 13 a subject swallows during scan acquisition and in Figure 14 
a subject with chronic obstructive pulmonary disease (COPD) has 
laboured breathing at rest with marked use of accessory muscles of 
respiration. 
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Figure 13: Screen capture of a subject swallowing during scan 
acquisition 
 
Legend: subject swallows at end of data capture demonstrating marked change in 
distension waveform, highlighted within the red circle. 
 
Figure 14: Screen capture of a subject breathing heavily during scan 
acquisition 
 
Legend: As a result of laboured breathing with use of accessory muscles in this subject, 
the TDI system is not able to accurately measure the ADW as highlighted in red. 
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Cardiac arrhythmias 
Due to the variability of beat to beat cardiac output in patients with 
cardiac arrhythmias such as atrial fibrillation, the pattern and maximum 
excursion of the ADW was extremely variable and thus unreliable. This is 
demonstrated in Figure 15. We also found that it was not possible to 
capture enough cardiac cycles in subjects with bradycardia due to the 
memory capacity of the ultrasound system, which was big enough only to 
capture 5 seconds of high resolution images. 
Figure 15: Screen capture of scan acquisition of a subject with atrial 
fibrillation 
 
Legend: In the presence of an arrhythmia, the TDI system is unable to identify the 
cardiac cycles, as highlighted in red. 
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Analysis of BCCOV  
After rejection of the 70 scans with failed wall recognition, subgroup 
analysis of the remaining scans, sorted by presence of no identified error, 
arrhythmia present or extra arterial movement present, confirmed that 
BCCOV was less when these two errors were not identified. These data 
are presented in Table 5. 
Table 5: Between cycle coefficient of variation (BCCOV) for 130 scans of 
the CCA from 65 subjects broken down by error type. 
error type number BCCOV (%) 
 
no error identified 
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5.62 
(3.64 - 7.60) 
 
extra-arterial movement 48 7.23 
(1.21 – 15.67) 
arrhythmia 8 20.99 
(1.69 - 40.29)  
Legend: Figures in brackets are the range calculated as the mean ±one SD. 
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Conclusions 
From this initial study and from information already available about the 
AWM system, the following criteria were developed to be used in further 
studies: 
 arterial diameter greater than 3 mm 
 no side branches 
 ensure subject is rested and comfortable on couch prior to scan 
acquisition for 5 minutes 
 exclude subjects with breathing difficulties 
 exclude subjects with cardiac arrhythmias 
 ensure scan plane alignment in ROI 
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8 
A REPRODUCIBILITY STUDY OF A TDI BASED 
METHOD TO CALCULATE INDICES OF ARTERIAL 
STIFFNESS 
The aim of the study was to investigate the reproducibility of estimation of Young’s 
modulus E and pressure strain elastic modulus Ep, derived from a tissue Doppler 
imaging (TDI) wall motion technique.  
Healthy subjects had their arteries insonated at the same sitting by two different 
observers and at two different sittings by the same observer. From 32 subjects in the 
reproducibility study, within-scan coefficient of variation (CV) was 4.5%. Intraobserver 
between-scan CV for E was 12.7% and for Ep 11.0%. Interobserver CVs were 8.3% and 
9.3%, respectively.  
TDI is a reproducible, valid and highly sensitive direct assessment of arterial 
wall parameters. It is at least as reproducible as other ultrasound based methods for 
assessing arterial stiffness and also provides increased information about the arterial 
distension waveform. 
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Introduction 
The aim of this study was to investigate the reproducibility of the TDI 
system in calculating E and Ep in the common carotid arteries (CCAs) of 
human subjects.  
 The hypothesis was that given that the TDI system is able to 
measure AWM in high resolution, it should provide estimations of E and 
Ep that are more reproducible than other available ultrasound based 
systems for calculating these parameters. 
Methods 
Study Design 
All subjects recruited into the study provided fully informed written 
consent. Ethical approval was granted by Birmingham East District 
Research and Ethics Committee. All subjects completed a questionnaire 
regarding past medical history, drug evidence and exercise tolerance. A 
subject was defined as healthy if there was no evidence of cardiovascular 
disease or associated disease states. 
Inter-observer and intra-observer reproducibility was assessed in 
healthy subjects. For inter-observer reproducibility, the same patient was 
assessed by two different observers at the same sitting. One observer 
had 1 years experience in ultrasonography, and the other had 8 years 
experience. Each observer was unaware of the measurements of the 
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other observer. For intra-observer reproducibility, the same subject was 
assessed by the same observer at two sittings on a different day at least 
24 hours apart. Each assessment consisted of scan acquisition of the left 
and right common carotid artery, and blood pressure measurement as 
described on page 54. A B-mode image of the insonated artery was taken 
at each scan acquisition to ensure that the same segment of artery was 
insonated repeatedly. MADC, internal arterial diameter and IMT were 
assessed separately and E and Ep were calculated separately using 
these data for each CCA. 
Statistical analysis 
After extraction and collation of the raw data using Microsoft Excel, the 
data were analysed using Stata 8.1 for Windows (STATA Stata 
Corporation, College Station, Texas, USA) in association with a 
statistician from the University of Birmingham. The results of the 
reproducibility study were analysed with Bland-Altman Plots and by 
calculating coefficients of variation. The coefficient of variation was 
defined as observer error (standard deviation of the mean difference 
between observations/√2) multiplied by 100 divided by the pooled mean 
values.  
Results 
 A total of 32 subjects were analysed in the inter-observer study and 30 
subjects were analysed in the intra-observer study. The mean age of the 
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study population was 43 years (range 18 – 72). The mean systolic blood 
pressure in the study group was 124 mmHg (range 94 – 184) and the 
mean diastolic blood pressure 75 mmHg (range 54 – 100). The Bland-
Altman plots of the inter-observer differences (Figure 16) and intra-
observer differences (Figure 17) showed that no relationship exists 
between the difference in measurement and the estimated true value. 
The within scan standard deviation of the difference between the 
measurements was 18 microns for the inter-observer study and 20 
microns for the intra-observer study. The within scan (variation between 
cardiac cycles with one scan) coefficient of variation (standard deviation/ 
mean, CV) was 14.5%. Reproducibility statistics between scans are 
summarised in Table 6. 
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Figure 16: Inter-observer Bland Altman plots 
a) Inter-observer plot of IMT variability 
 
b) Inter-observer plot of Ep variability 
 
c) Inter-observer plot of E variability 
 
Legend: Bland-Altman plots showing inter-observer variability for calculated indices as 
measured in 32 arteries by two ultrasonographers. The difference between the two 
measurements plotted on the y-axis against the average of the two measurements on 
the x-axis. The horizontal lines depict the mean difference (bias) and the limits of 
agreement (bias ±2 SD) between the measurements. 
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Figure 17: Intra-observer Bland Altman plots 
a) Intra observer plot of IMT variability 
 
b) Intra observer plot of Ep variability 
 
c) Intra observer plot of E variability 
 
Legend: Bland-Altman plots showing intra-observer variability for calculated indices as 
measured in 32 arteries by two ultrasonographers. The difference between the two 
measurements plotted on the y-axis against the mean of the two measurements on the 
x-axis. The horizontal lines depict the mean difference (bias) and the limits of agreement 
(bias ±2 SD) between the measurements. 
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Table 6: Mean values and CV for indices measured in reproducibility 
study. 
 Inter- observer  study Intra- observer  study 
 LCCA RCCA combined LCCA RCCA combined 
d 
(mm) 
6.14* 
(5.27-8.65) 
6.12† 
(5.08-8.70) 
2.2% 
0.19 
 
6.37* 
(5.19-8.61) 
6.37† 
(5.28-8.32) 
3.2% 
0.29 
6.25* 
(5.36-8.42) 
6.25† 
(5.23-8.43) 
2.1% 
0.18 
6.33‡ 
(5.08-8.70) 
6.20§ 
(5.19-8.79) 
3.3% 
0.30 
6.45‡ 
(5.37-8.61) 
6.43§ 
(5.39-8.42) 
2.5% 
0.23 
6.38‡ 
(5.51-8.43) 
6.31§ 
(5.51-8.54) 
2.1% 
0.18 
IMT  
(mm) 
0.70* 
(0.51-1.05) 
0.70† 
(0.52-1.16) 
4.6% 
0.05 
 
0.66* 
(0.23-0.94) 
0.67† 
0.27-0.84) 
5.8% 
0.05 
0.68* 
(0.37-0.94) 
0.69† 
(0.46-0.99) 
4.0% 
0.03 
0.70‡ 
(0.40-1.63) 
0.69§ 
(0.51-1.16) 
7.5% 
0.07 
0.63‡ 
(0.21-1.12) 
0.63§ 
(0.35-1.14) 
8.3% 
0.07 
0.67‡ 
(0.39-1.38) 
0.66§ 
(0.44-1.15) 
6.3% 
0.07 
Ep 
(mmHg) 
116* 
(63-205) 
106† 
(57-226) 
12.3% 
19.4 
 
115* 
(56-246) 
109† 
(58-301) 
13.5% 
21.4 
116* 
(59-198) 
107† 
(58-226) 
9.3% 
14.8 
119‡ 
(57-515) 
116§ 
(57-249) 
12.0% 
19.9 
107‡ 
(58-301) 
102§ 
(56-236) 
14.6% 
21.4 
112‡ 
(58-325) 
109§ 
(444-1651) 
11.0% 
34.8 
E  
(mmHg) 
516* 
(237-814) 
473† 
(221-996) 
13.4% 
94.2 
574* 
(813-1319) 
573† 
(301-1424) 
17.3% 
136 
545* 
(283-980) 
523† 
(261-1059) 
8.3 % 
25.7 
551‡ 
(221-1254) 
528§ 
(285-1118) 
14.9% 
114 
571‡ 
(273-1384) 
531§ 
(285-1068) 
17.3% 
134 
561‡ 
(287-1039) 
530§ 
(301-1093) 
12.7% 
32.6 
Legend: * first observer; †second observer; ‡ first session; § second session; value in 
bold = coefficient of variation; values in brackets = range; value in italics = standard 
deviation; IMT = intima-media thickness; Ep = Elastic modulus; E = Young’s modulus. 
Discussion 
This study has demonstrated for the first time that TDI is a reproducible is 
and valid method of analysing the elastic properties of arteries. The 
reproducibility of our measurements is at least as good as the best 
reported in the literature using conventional B-mode based techniques240. 
The reproducibility is also improved when compared to methods using 
echo tracking.241 Ultrasound is often criticised for its operator 
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dependence. This study demonstrated excellent reproducibility between 
both observers, one of whom had only one year’s experience. TDI scans 
along many points of the segment of artery of interest at a higher frame 
rate than other ultrasound based methods, and we believe this is the 
main reason behind the improved results. Central pulse wave velocity 
estimation demonstrates similar reproducibility to our method, but is not a 
direct assessment of arterial stiffness.242 The range of values for E and 
Ep that we have calculated in healthy subjects is similar to that estimated 
in previous studies.243  
We have shown that the left CCA demonstrated superior 
reproducibility to the right. The left CCA is anatomically the most closely 
related to the aorta, arising directly from the aortic arch, as opposed to 
the right CCA which arises indirectly from the aorta via the 
brachiocephalic trunk. Thus the left CCA is thought to be most likely to 
reflect the qualities of the central aorta. We believe that the left CCA is 
the best site to measure CCA stiffness, particularly when the results are 
used as a measure of systemic arterial stiffness. 
Conclusions 
TDI is a reproducible, valid and highly sensitive direct assessment of 
arterial wall stiffness, which suggests that the increased stiffness in 
subjects with PAD is not just a function of increased wall thickness or 
diameter, but possibly a change in arterial wall structure as well.  
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9 
RELATIONSHIP BETWEEN AGE AND ARTERIAL 
STIFFNESS 
 
It remains difficult to decide whether the cardiovascular effects of increased age are 
separate to that of atherosclerosis. Increased arterial stiffness, PP and IMT have all 
been shown to be associated with increased age. The aim of this chapter was to 
examine the relationship between E, Ep, PP, IMT and increased age in a cohort of 
healthy subjects. 
The arterial distension waveform, IMT, diameter and brachial blood pressure 
were measured to calculate E, Ep in the common carotid arteries of subjects.121 
subjects (age 5-83 years) were examined. E, Ep, SBP, DBP, d (all p<0.0001), IMT 
(p=0.014) and PP (p= 0.002) were all significantly associated with increased age. The 
regression coefficient was greater for E (10.64) and Ep (2.59) than for PP (0.161), IMT 
(0.001), SBP (0.45), DBP (0.355) and d (0.023). Correlation with age was higher for E 
(0.71) and Ep (0.81) than PP (0.19), IMT (0.24), SBP (0.59), DBP (0.59) and d (0.52). 
This change was maintained across all percentiles for all parameters. 
 We have shown for the first time in a cross sectional study that E and Ep have a 
stronger relationship with increased age than IMT or PP, early markers of 
atherosclerosis. This suggests that the first changes in ageing may be the development 
of increased arterial stiffness rather than atherosclerosis. 
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Introduction 
Qualitative changes in cardiovascular physiology with age have been 
recorded for over one hundred years.15,75 Interest in the quantitative limits 
of blood pressure gained favour over the qualitative form with the 
emergence off the cuff sphygmomanometer. It is only more recently that 
interest in the qualitative from of arterial blood pressure has once again 
emerged with the study of arterial stiffness.  
There is controversy surrounding much recent research 
concerning vascular ageing. The reasons for this include a lack of an 
accurate animal model to simulate human cardiovascular ageing,76-79 
inaccuracy of non-invasive investigations, difficulty in discriminating the 
difference between natural ageing and occult disease, controversy over 
what the natural ageing process actually is, and difficulty in identification 
of the reserve physiological capability of cardiovascular and other organs. 
However, the main functional change with increasing age appears to be 
progressive stiffening of the central aorta with subsequent effect on 
cardiac function.15,83 Increased aortic stiffness with age has been found in 
both western populations with a high propensity towards atherosclerosis 
and other populations not prone to atherosclerosis.84-88 It is therefore is 
believed to be a genuine age dependent change. At any particular age 
there is a wide range of arterial stiffness.89 
Increased carotid IMT has been shown to be a good indicator of 
generalised atherosclerosis,54 as well as a predictor of cardiovascular 
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events.244-246 This relationship is presumed to exist as increased carotid 
IMT represents mainly increased intimal thickening in the elastic carotid 
artery.54 Similarly increased CCA diameter has been shown to be a 
marker of atherosclerotic change.247 However, increased IMT and 
diameter may be late markers of atherosclerotic changes in the arterial 
wall. 
PP is the difference between systolic and diastolic blood pressure. 
It has long been recognized as a valuable surrogate marker of arterial 
stiffness15 as it depends on cardiac output, large artery stiffness and 
wave reflection. Both SBP and DBP increase with age. However, beyond 
the sixth decade, DBP does not increase whereas SBP continues to do 
so. Thus pulse pressure increases with age.13 PP takes no account of 
change in volume and therefore is not a true measure of arterial stiffness. 
Data from the Framingham study demonstrates that PP predicts the risk 
of coronary heart disease better in a population over the age of 50 years 
than SBP or DBP measurements alone.18 
The aim of this study was to investigate indices of arterial stiffness, 
blood pressure and IMT in the CCAs of healthy subjects of different ages. 
The hypothesis was that indices of arterial wall stiffness would 
increase more than IMT with age in healthy subjects. 
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Methods 
Study design 
All subjects recruited into the study provided fully informed written 
consent. Ethical approval was granted by Birmingham East District 
Research and Ethics Committee. All potential subjects were screened 
using a questionnaire regarding past medical history and drug evidence. 
The relationship between age and arterial stiffness was measured 
in healthy volunteers. Subjects recruited were either members of staff at 
Heart of England NHS Trust or were known to them. All subjects 
answered a detailed questionnaire to look for evidence of disease and all 
potential subjects with any significant past medical history were excluded 
from the study. Therefore, only subjects who had no history of diabetes, 
hypertension, cardiovascular disease (including PAD, CAD and CVD), 
chronic kidney disease (CKD) and respiratory disease were included in 
the study. In addition subjects were not accepted into the study if they 
were taking any form of regular medication. 
Statistical analysis 
After extraction and collation of the raw data using Microsoft Excel, the 
data were analysed using Stata 8.1 for Windows (STATA Stata 
Corporation, College Station, Texas, USA). 
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Results 
120 subjects were recruited ranging from 5 to 83 years of age. 50 (43%) 
were male. Mean SBP was 123 mmHg (range 89-169 mmHg) and mean 
DBP was 73mmHg (range 41-110mmHg). These demographics are 
further detailed in Table 7 and segregated per decade, together with 
mean values per decade for PP, d, IMT, E and Ep. We found that E, Ep, 
SBP, DBP, d (all p<0.0001), IMT (p=0.014) and PP (p= 0.002) were all 
significantly associated with increasing age when analysed with linear 
regression. The regression coefficient was greater for E (10.64) and Ep 
(2.59) than for PP (0.161), IMT (0.001), SBP (0.45), DBP (0.355) and d 
(0.023). In addition the correlation with age was also higher for E (0.71) 
and Ep (0.81) than PP (0.19), IMT (0.24), SBP (0.59), DBP (0.59) and d 
(0.52). These data are presented in Table 8. Regression plots of these 
relationships are found in Figures 18-24. 
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Table 7: Main characteristics of study population split into decades 
age 
(years) 
no male SBP 
(mmHg) 
DBP 
(mmHg) 
PP 
(mmHg) 
d 
(mm) 
IMT 
(mm) 
E 
(kPa) 
Ep 
(kPa) 
 
0-9 21 7 
(33) 
108 
(88-125) 
 
60 
(42-96) 
47 
(23-62) 
5.6 
(4.6-6.6) 
0.67 
(0.58-0.93) 
207 
(73-536) 
49 
(23-119) 
10-19 40 23 
(57) 
119 
(103-143) 
 
63 
(50-80) 
55 
(37-70) 
5.7 
(4.5-7.5) 
0.69 
(0.45-1.03) 
282 
(106-533) 
64 
(41-131) 
20-29 12 4 
(33) 
117 
(99-133) 
 
68 
(58-85) 
49 
(35-66) 
6.6 
(5.1-7.8) 
0.72 
(0.59-1.33) 
377 
(229-556) 
 
79 
(49-97) 
30-39 24 7 
(29) 
121 
(104-143) 
69 
(57-94) 
 
51 
(33-63) 
6.4 
(5.1-7.2) 
0.70 
(0.56-0.96) 
477 
(269-1296) 
101 
(64-200) 
40-49 11 4 
(36) 
127 
(120-137) 
 
74 
(65-83) 
53 
(38-69) 
6.7 
(5.9-8.2) 
0.68 
(0.48-0.94) 
 
660 
(231-1303) 
123 
(71-193) 
50-59 5 3 
(60) 
131 
(111-146) 
 
79 
(64-96) 
53 
(48-57) 
7.1 
(6.4-8.3) 
0.73 
(0.62-0.83) 
757 
(364-1299) 
153 
(89-265) 
60-69 3 1(33) 144 
(114-170) 
 
81 
(65-90) 
63 
(49-80) 
6.4 
(5.8-7.0) 
0.88 
(0.68-1.05) 
682 
(542-813) 
 
188 
(127-229) 
70-79 2 1 
(50) 
141 
(119-162) 
 
86 
(75-86) 
60 
(44-77) 
6.7 
(6.5-6.9) 
0.84 
(0.76-0.93) 
1045 
(731-1359) 
 
253 
(207-298) 
80-89 2 1 
(50) 
170 
(163-177) 
85 
(73-95) 
84 
(73-95) 
6.5 
(5.8-7.3) 
0.91 
(0.91-0.93) 
785 
(785-890) 
317 
(245-390) 
Legend: figures are mean values per decade with 95% confidence intervals in brackets, 
except for male category where figure in brackets is percentage per decade; SBP, DBP 
and PP in mmHg; d and IMT in mm; E and Ep in KPa. 
 
Table 8: Regression coefficients and correlation between experimental 
variables and age 
variable regression 
coefficient 
t p value R2 correlation  
with age
 
E 
 
10.64 
 
11.02 
 
<0.0001 
 
0.51 
 
0.71 
Ep 2.597 15.48 <0.0001 0.67 0.81 
PP 0.161 3.14 0.002 0.07 0.19 
SBP 0.45 7.45 <0.0001 0.37 0.59 
DBP 0.355 7.46 <0.0001 0.36 0.59 
IMT 0.001 2.50 0.014 0.04 0.24 
diameter 0.023 6.69 <0.0001 0.27 0.52 
Legend: PP=pulse pressure (mmHg); IMT=intima-media thickness (mm); E= Young’s 
modulus (KPa); Ep=elastic modulus (KPa); SBP=systolic blood pressure (mmHg); 
DBP=diastolic blood pressure (mmHg); d=diameter (mm). 
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Figure 18: Regression graph of Young’s modulus plotted against age 
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Legend: red line is plot of linear regression of Young’s modulus against age 
 
Figure 19: Regression graph of Peterson’s elastic modulus plotted 
against age 
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 Legend: red line is plot of linear regression of Peterson’s elastic modulus against age 
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Figure 20: Regression graph of systolic blood pressure plotted against 
age 
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Legend: red line is plot of linear regression of systolic blood pressure against age 
 
Figure 21: Regression graph of diastolic blood pressure plotted against 
age 
40
60
80
10
0
di
as
to
lic
 b
lo
od
 p
re
ss
ur
e 
in
 m
m
H
g
0 20 40 60 80
age in years
 
Legend: red line is plot of linear regression of diastolic blood pressure against age 
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Figure 22: Regression graph of pulse pressure plotted against age 
20
40
60
80
10
0
pu
ls
e 
pr
es
su
re
 in
 m
m
H
g
0 20 40 60 80
age in years
 
Legend: red line is plot of linear regression of pulse pressure against age 
 
Figure 23: Regression graph of diameter plotted against age 
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Legend: red line is plot of linear regression of diameter against age 
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Figure 24: Regression graph of IMT plotted against age 
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Legend: red line is plot of linear regression of intima media thickness against age 
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Discussion 
We have shown that E and Ep have the strongest relationship with 
increased age when compared to early markers of atherosclerosis (IMT 
and PP) in a cross sectional study of healthy subjects with an age range 
of 5 to 83 years. We believe that this suggests that the first 
cardiovascular changes in ageing may be increased arterial stiffness 
rather than these changes being secondary to the development of 
atherosclerosis. These findings would appear to fit with the histological 
observations that the most significant arterial change with ageing is in the 
arterial media, where there is  loss of the orderly arrangement of elastin 
fibres which also undergo thinning splitting, fraying and fragmentation 
together with an increase in collagen and ground substance,82 and a 
decrease in the amount of smooth muscle.82 Atherosclerosis is 
predominantly a disease of the intima and we would have expected to 
observe a stronger relationship between IMT and age if the major change 
in cardiovascular ageing was atherosclerosis. We accept that the only 
place that we have measured IMT is in the CCA. However this is the most 
commonly measured site, and is a well recognised marker for early 
atherosclerotic change.239 
In line with other studies of this nature we have used data from the 
left CCA only. This artery demonstrated superior reproducibility to the 
right in our reproducibility study.248 The left CCA is anatomically the most 
closely related to the aorta arising directly from the aortic arch as 
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opposed to the right CCA which arises indirectly from the aorta via the 
brachiocephalic trunk. Thus the left CCA is thought to be most likely to 
reflect the qualities of the central aorta. In addition, previous research 
only supports evidence of increased arterial stiffness in the aorta and 
other central elastic arteries, with little evidence being found for a change 
in stiffness with age in the muscular arteries such as the brachial, radial 
or femoral,36,86,90 so we believe that the left CCA is a good site to 
measure arterial stiffness in this particular study. 
Our aim was only to recruit healthy volunteers into the study. This 
is difficult to achieve without detailed testing of each potential recruit. We 
believe that we achieved this aim via stringent screening criteria, but we 
accept that subjects with occult disease may still have been accepted into 
the study. Serum lipid profiles could help in identifying potential subjects 
with occult cardiovascular disease, but these were not taken in this study 
population. We recognise that this cross sectional study may only include 
survivors in any age group, particularly with increasing age who are able 
to withstand the effects of cardiovascular ageing.80 However a 
prospective cohort study would be the only way to confirm or refute this, 
which would necessarily take at least a lifetime to complete.  
The DBP rose with age in our study population, which was not 
expected, as most studies examining blood pressure and age have found 
that it decreases with age. This may be a sampling error. 
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Conclusions 
We have shown that markers of arterial stiffness are more increased with 
increased age than markers of atherosclerosis. We believe that this study 
provides further evidence that the process of cardiovascular ageing is 
associated with increased arterial stiffness and subsequent functional 
change as a result of a ‘worn out’ arterial media. It is possible that this 
process is separate from atherosclerosis, although may predispose an 
individual to develop it. 
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10 
MEASUREMENT OF ARTERIAL STIFFNESS IN 
SUBJECTS WITH VASCULAR DISEASE: ARE 
VESSEL WALL CHANGES MORE SENSITIVE THAN 
INCREASE IN INTIMA-MEDIA THICKNESS? 
It is widely accepted that subjects with vascular disease have increased arterial stiffness 
and IMT when compared with healthy controls. The aim of this study was to investigate 
indices of arterial stiffness and IMT in the CCAs of subjects with and without PAD, in 
order to look for evidence of change in wall quality and quantity to explain increased 
stiffness that has been found in the arteries of subjects with vascular disease. 
The ADW, IMT, d and BP were measured to calculate E and Ep in 38 subjects 
with confirmed PAD and 43 normal controls matched for age, sex, smoking and 
hypertension. The mean diameter (8.35mm [95% CI 7.93–8.77] vs.6.93mm [6.65–7.20] 
P < 0.001, increase 20%), IMT (0.99mm [0.92–1.07] vs. 0.88mm [0.82–0.93] P = 0.020, 
increase 12.5%), Ep (315 kPa [185–444] vs. 190 kPa [164–216] P = 0.034, increase 
66%) and E (1383 kPa [836–1930] vs. 744 kPa [641–846] P = 0.006, increase 86%) 
were all significantly higher in subjects with PAD. 
This study suggests that increased stiffness observed in subjects with peripheral 
vascular disease is a result of change in both quantity and quality of the arterial wall. 
Changes in indices of arterial stiffness were much higher than changes in IMT and 
diameter. These preliminary observations may be an indication that indices of arterial 
stiffness are a sensitive early marker of atherosclerosis. 
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Introduction 
An enlarging body of evidence suggests that increased arterial stiffness is 
associated with markers of cardiovascular risk and that this stiffness may 
herald the onset of cardiovascular disease before manifestation of 
symptoms or detection of frank atherosclerotic lesions.249,250 
Measurement of arterial stiffness could become a part of the process of 
both risk assessment and monitoring of therapy in patients with 
cardiovascular disease. 
Patients with atherosclerosis have changes in the arterial wall, 
such as the formation of atherosclerotic plaques together with a varying 
degree of in situ thrombosis, and fibrosis and calcification of the tunic 
media. Increased wall thickness is also often demonstrated.239 PAD is 
usually a reflection of a systemic atherosclerotic disease.251 We 
hypothesise that material stiffness changes at a different rate from 
structural stiffness in patients with and without PAD. 
The aim of this study was to investigate markers of material and 
structural arterial stiffness (E and Ep) and wall thickness (IMT) in the 
CCAs of human subjects with and without evidence of PAD in order to 
study which variable changes the most in affected subjects. 
The hypothesis was that changes in stiffness parameters of the 
arterial wall would be greater than changes in IMT in subjects with PAD 
when compared to a healthy matched control population. 
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Methods 
Study design 
All subjects recruited into the study provided fully informed written 
consent. Ethical approval was granted by Birmingham East District 
Research and Ethics Committee. All subjects completed a questionnaire 
regarding past medical history and drug evidence.  
 
Subject Selection 
The elastic properties of CCAs in age- and sex- matched subjects with 
and without evidence of PAD were compared. Subjects with PAD were 
recruited from a dedicated nurse led outpatient clinic at the Heart of 
England NHS Foundation Trust for subjects with non disabling lower limb 
claudication, who had opted to have conservative treatment for their 
symptoms. Their claudication symptoms were stable for at least 6 
months. Prospective control population subjects were recruited from non 
vascular outpatient clinics at the same hospital. These subjects were 
attending hospital with non cardiovascular problems such as herniae, 
simple skin lesions and benign urological disease. All participants were 
subject to similar scrutiny in order to determine their vascular status. 
Subjects were deemed free from PAD if they had an unlimited walking 
distance and an ABPI greater than 0.9. Similarly all patients with PAD 
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had a confirmed history of lower limb claudication and an ABPI of less 
than 0.9. 
Statistical analysis 
After extraction and collation of the raw data using Microsoft Excel, the 
data were analysed using Stata 8.1 for Windows (STATA Stata 
Corporation, College Station, Texas, USA) in association with a 
statistician from the University of Birmingham. Mean values in the case 
population and the control population were compared using Student’s t-
test after log transformation.  
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Results 
We assessed the left common carotid artery (LCCA) in 38 cases with 
evidence of PAD and 43 healthy controls. Both populations were well 
matched for age, sex and co-existing risk factors as demonstrated in 
Table 9. Co existing medication is listed in Table 10. As can be seen, the 
PAD group had a higher incidence of Statin use than the control group, 
but otherwise there is no other significant difference in cardiovascular 
medication between the two groups. Cases with PAD had a significantly 
increased E and Ep, diameter and IMT compared to subjects without 
PAD (Table 11). Interestingly, the increases in indices of stiffness, in 
particular material stiffness seen in subjects with PAD were higher 
compared to the increases seen in IMT and diameter. E was found to be 
86% greater in the PAD group compared to the control group and Ep 
66% greater. In comparison, diameter was only 20% greater and IMT 
12.5% greater. All the results were statistically significant when analysed 
using Students t-test after log transformation. 
 
Table 9: Main characteristics of study populations. 
 No. 
 
Age 
(range) 
Male
(%) 
SBP
(95% CI) 
Smoki
ng 
(%) 
↑BP
(%) 
 
CAD
(%) 
CVD 
(%) 
DM
(%) 
 
PAD 
 
38 
 
69 
(55-85) 
 
32 
(84) 
 
154 
(106-203) 
 
25 
(68) 
 
20 
(52) 
 
3 
(8) 
 
2 
(5) 
 
6 
(16) 
 
Control 43 67 
(55-82) 
33 
(77) 
154 
(110-203) 
30 
(69) 
17 
(40) 
4 
(9) 
3 
(7) 
5 
(12) 
Legend: PAD= peripheral arterial disease; SBP =  systolic blood pressure; ↑BP= 
hypertension; CAD=coronary artery disease; CVD= cerebrovascular disease; DM= 
diabetes mellitus 
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Table 10: concurrent drug therapy for study populations 
 No. of 
subjects 
Statin diuretic ca 
antagonist 
nitrate B-
blocker 
ACE-
I 
 
PAD 
 
38 
 
28 
(74) 
 
8 
(21) 
 
6 
(16) 
 
2 
(5) 
 
2 
(5) 
 
0 
(0) 
 
Control 43 6 
(14) 
10 
(23) 
6 
(14) 
4 
(9) 
5 
(12) 
6 
(14) 
Legend: ACE-I = angiotensin converting enzyme inhibitor; figure in brackets is 
percentage 
 
 
 
Table 11: Wall properties of study populations.  
 no. of 
subjects 
IMT
mm 
diameter
mm 
Ep 
KPa 
E 
KPa 
 
PAD 
 
38 
 
0.99  
(0.92-1.07) 
 
 
8.35 
(7.93-8.77) 
 
315  
(185 – 444) 
 
1383  
(836-1930) 
control 43 0.88  
(0.82-0.93) 
 
6.93 
(6.65-7.20) 
190  
(164 – 216) 
744  
(641 – 846) 
increase  12.5% 
 
20% 66% 86% 
p value  0.020 < 0.001 0.034 0.006 
Legend: IMT = intima-media thickness; Ep = Elastic modulus; E= Young’s modulus; 
mean values and 95% confidence intervals in brackets; p values calculated with the 
Student’s t-test after log transformation 
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Discussion 
We have shown that arterial diameter, IMT, E and Ep are significantly 
increased in subjects with PAD compared to controls without PAD. We 
are not aware of any study that has compared E and Ep in subjects with 
and without PAD. Differences in arterial stiffness between subjects with 
and without PAD have been shown before.150,151 Increased carotid IMT 
has been shown to be a good indicator of generalised atherosclerosis54, 
as well as a predictor of cardiovascular events.244-246 This relationship is 
presumed to exist as increased carotid IMT represents mainly increased 
intimal thickening in the elastic carotid artery.54 Similarly increased CCA 
diameter has been shown to be a marker of atherosclerotic change.247 
However, increased IMT and diameter may be late markers of 
atherosclerotic changes in the arterial wall. We demonstrated changes in 
the elastic properties of the arterial wall which are independent 
variables,24 and are thought to reflect material as well as structural 
change. The increase in E in the PAD group was mostly due to the 
increase in Ep as the increase in IMT and diameter in that group, as can 
be seen from the formula for E (page 12), partly balance each other out. 
Our findings suggest that both E and Ep increase more than IMT 
and diameter in subjects with PAD. The change in E (86%) was nearly 
seven times greater than IMT (12.5%) and more than four times greater 
than diameter (20%) when compared to controls. Similarly, the change in 
Ep (66%) was more than five times greater than IMT (12.5%) and more 
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than three times greater than diameter (20%). Based on this, we believe 
that markers of arterial stiffness, particularly those indicating material 
change in the arterial wall (such as E) could be a more sensitive index of 
developing atherosclerosis than structural measurements alone such as 
change in IMT and diameter, that may even change before IMT does. 
This is because these indices describe the relationship between stress 
and strain whereas IMT and diameter report the result of a change in this 
relationship. There is some evidence in the literature to support this 
hypothesis. Giannattasio et al found that increased arterial stiffness, 
measured as reduced carotid artery distensibility, was present in 
normotensive normoglycaemic offspring of type 2 diabetic parents, when 
compared to a control group.252 However, there was no change in IMT 
between the two groups.  
As demonstrated in Table 9, the PAD group had a higher 
incidence of Statin use than the control group as a result of best medical 
therapy intended to limit progression of known cardiovascular disease 
and prevent secondary cardiovascular events. We do not believe that this 
discrepancy affects the result, as published literature suggests that Statin 
use decreases rather than increases arterial stiffness.207  
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Conclusions 
This study has shown a significant difference in E and Ep, diameter and 
IMT in the CCAs of subjects with and without PAD, which suggests that 
the increased stiffness in subjects with PAD is not just a function of 
increased wall thickness or diameter, but a change in arterial wall 
structure as well. The change in indices of arterial stiffness was much 
greater than the changes in IMT or diameter. We believe that this is 
because changes in arterial stiffness are an indication of a change in the 
relationship between strain and stress on the arterial wall, rather than 
changes in diameter or IMT which are a result of this change. It is 
possible therefore that atherosclerotic change may be herald at an earlier 
point by noting a change in arterial stiffness rather than a change in the 
structure of the arterial wall, and we recommend that prospective 
research is carried out in this area to confirm or refute this. 
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11 
ARTERIAL STIFFNESS IN WITH RENAL DISEASE: 
ARE CHANGES IN THE VESSEL WALL EARLIER 
MARKERS OF CARDIOVASCULAR DISEASE THAN 
IMT AND PULSE PRESSURE? 
There is increased cardiovascular mortality in subjects with ESRD. Arterial stiffness in 
these subjects is increased when compared to a healthy population and has been 
shown to be a strong predictor of mortality. The aim of this study was to investigate the 
relationship between markers of cardiovascular disease and subjects with no, mild and 
severe CKD. 
The arterial distension waveform, IMT, diameter and brachial blood pressure 
were measured to calculate E and Ep in the common carotid arteries of subjects with 
and without CKD. Data was available for 15 patients with normal kidney function and no 
evidence of cardiovascular disease, 29 patients with mild CKD (eGFR 89 to 60) and 24 
patients with severe CKD (eGFR < 30). Age, cardiovascular disease, hypertension, 
hyperlipidaemia, PP, Ep and E were all significantly associated with renal disease. Only 
age, E and Ep were significantly different between healthy subjects and those with mild 
renal impairment. Logistic regression demonstrated that only Ep and E were 
independently associated with mild renal disease compared to normal, in a model 
adjusting for sex, age and diabetes. Only E was independently associated with severe 
renal disease compared to non-severe renal disease in the same model adjusting for 
age sex and diabetes. 
E and Ep may be early markers of cardiovascular disease in subjects with CKD 
that may manifest change before other more recognized markers such as IMT and PP. 
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Introduction 
It is well recognized that subjects with ESRD have increased mortality 
when compared to healthy controls. With unrestricted access to renal 
dialysis, this annual mortality of approximately 10% is largely secondary 
to cardiovascular complications of ESRD rather than death from renal 
failure per se.253-255 Subjects with ESRD have been shown to have 
increased arterial stiffness.256 In addition increased arterial stiffness has 
been shown to be a strong independent predictor of both cardiovascular 
and all cause mortality in these subjects.180,257,258 It is probable that 
cardiovascular disease starts to develop early in CKD. Even mild to 
moderate renal insufficiency is associated with increased risk of 
developing cardiovascular disease and death from it.259 Increased arterial 
stiffness in renal transplant patients appears to correlate strongly with the 
length of time on dialysis, suggesting that the duration rather than the 
degree CKD may be more important in the development of cardiovascular 
disease.183 
Increased carotid IMT has been shown to be a good indicator of 
generalised atherosclerosis,54 as well as a predictor of cardiovascular 
events.244-246 This relationship is presumed to exist as increased carotid 
IMT represents mainly increased intimal thickening in the elastic carotid 
artery.54 Similarly increased CCA diameter has been shown to be a 
marker of atherosclerotic change.247 However, increased IMT and 
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diameter may be late markers of atherosclerotic changes in the arterial 
wall. 
The aim of this study was to investigate the relationship between IMT, PP 
and indices of arterial stiffness in subjects with different stages of CKD in 
order to gain information as to which markers of cardiovascular disease 
may change first in patients with renal disease. 
 The hypothesis was that indices of arterial wall stiffness would 
increase more than IMT and PP in subjects with increasing severity of 
CKD. 
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Methods 
Study design 
All subjects recruited into the study provided fully informed written 
consent. Ethical approval was granted by Birmingham East District 
Research and Ethics Committee. All subjects completed a questionnaire 
regarding past medical history and drug evidence.  
 
 
Subject Selection 
The elastic properties of CCAs in subjects with different stages of CKD 
were compared. Subjects with CKD were recruited from renal outpatient 
clinics at the Heart of England NHS Foundation Trust. Prospective 
healthy subjects were recruited from non renal outpatient clinics at the 
same hospital. These subjects were attending hospital with non 
cardiovascular problems such as herniae, simple skin lesions and benign 
urological disease. All participants were subject to similar scrutiny in order 
to determine their renal status. No subjects were receiving renal 
replacement therapy. 
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Calculation of CKD stage 
The absence of kidney disease was defined by proteinuria of less than 
300 mg/day and by a glomerular filtration rate (GFR) above 90 ml/min, 
demonstrated on samples taken within 6 months of participation in this 
study. If the GFR was 60-89 mlmin-1, kidney function was assumed to be 
normal if diabetes and hypertension were also absent and a kidney 
ultrasound demonstrated normal appearances. All other instances 
suggested the presence of kidney disease. Stages of chronic kidney 
disease were defined according to the level of GFR as recommended by 
the National Kidney Foundation guideline Kidney Disease Outcomes 
Quality Initiative  clinical practice guidelines for chronic kidney disease.260 
The GFR was estimated from a blood sample (serum creatinine), using 
the Modification of Diet in Renal Disease Study equation,261 and 
proteinuria was estimated from a spot urine sample (protein-creatinine 
ratio). 
Subjects were recruited and divided into three distinct groups. Normal (no 
evidence of kidney or cardiovascular disease), Mild (eGFR 89 to 60 
mlsmin-1, CKD stage 2) and Severe (eGFR less than 30 mlsmin-1, CKD 
stage 4 or 5). 
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Statistical analysis 
After extraction and collation of the raw data using Microsoft Excel, the 
data were analysed using Stata 8.1 for Windows (STATA Stata 
Corporation, College Station, Texas, USA). 
Results 
We assessed elastic properties of the left CCA in 68 subjects, 15 in the 
normal group, 29 in the mild group and 24 in the severe group. Subject 
demographics and coexisting morbidity are detailed in Table 12. 
Univariate analysis demonstrated significant correlation between renal 
disease and age, cardiovascular disease, hypertension, hyperlipidaemia, 
PP, Ep and E. These relationships were maintained when subjects from 
the mild and moderate renal failure group were compared, but were only 
present for age, Ep and E when subjects from the normal renal function 
group and mild renal failure group were compared. IMT was not found to 
be significantly correlated with renal status in any comparison. These 
data are presented in more detail in Table 12. 
We used logistic regression to look for predictors of change 
between the Normal group and the Mild group, and the Mild group and 
the Severe group. The model used in both instances included age, sex 
and diabetes. We found that E, Ep and age were independently 
associated when comparing the Normal and Mild group. Notably, IMT and 
PP were not. Comparing the Mild and Severe group, age and E were 
significantly associated, but Ep, IMT and PP were not. These data are 
106 
 
presented in more detail in Table 13. Box plots of E, Ep, PP and IMT 
against renal group are shown in Figures 25-28. 
 
Table 12: Main characteristics of study population divided per renal 
group.  
characteristic normal mild severe prob. of  
overall  
trend 
prob. of  
trend 
normal  
to mild 
group 
prob. of 
trend 
mild to 
severe 
group 
 
number 
 
15 
 
29 
 
24 
   
male sex* 10(67) 20(69) 17(70) NS NS NS 
age† (years)  47±15 57±14 69±14 <0.0001 0.0243 0.0065 
CVD* 0(0) 4(13) 9(37) 0.0083 0.1376 0.0045 
DM* 3(20) 3(10) 6(24) NS NS NS 
hypertension* 2(13) 8(27) 20(83) <0.0001 0.2958 <0.0001 
hyperlipidaemia* 2(13) 3(10) 10(59) 0.0003 0.7736 0.0002 
eGFR† (ml/min) 95±9 73±7 16±4 <0.0001 <0.0001 <0.0001 
SBP† (mmHg) 141±19 146±27 156±29 NS NS NS 
DBP† (mmHg) 81±11 84±14 77±9 NS NS NS 
PP† (mmHg) 59±14 62±17 77±24 0.0056 0.519 0.0104 
diameter† (mm) 6.9±0.9 7.0±0.8 7.2±1.1 NS NS NS 
Ep† (KPa) 120±48 177±104 268±174 <0.0001 0.0009 0.0102 
E† (KPa) 549±281 676±378 1091±607 <0.0001 0.0005 0.0144 
IMT† (mm) 0.84±0.24 0.81±0.19 0.88±0.20 NS NS NS 
Legend: prob.=probability; CVD=cerebrovascular disease; DM=diabetes mellitus; 
GFR=glomerular filtration rate; SBP=systolic blood pressure; DBP=diastolic blood 
pressure; PP=pulse pressure; Ep=Peterson’s elastic modulus; E=Young’s modulus; 
IMT=intima media thickness; *figure in brackets represents percentage per population; 
†values expressed as mean ± SD. Probability for trend calculated using one way 
ANOVA. 
107 
 
Table 13: Results of logistic regression model looking for predictors for 
change between Normal and Mild group and then Mild and Severe group. 
parameter Normal to Mild Mild to Severe 
age 0.008 0.001 
PP NS NS 
IMT NS NS 
E 0.019 0.039 
Ep 0.031 NS 
sex NS NS 
diabetes NS NS 
Legend: PP=pulse pressure; IMT=intima media thickness; E=Young’s modulus; 
Ep=Peterson’s elastic modulus; model included age, sex and diabetes. Figure indicated 
is p value for each variable; NS indicates p value greater than 0.05. 
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Figure 25: Box plot of Young’s modulus per renal group 
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Legend: E=Young’s modulus; renal group represented in order across x-axis, Normal, 
Mild, Severe; scale on y-axis in KPa. 
 
Figure 26:Box plot of Peterson’s elastic modulus per renal group 
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Legend: Ep= Peterson’s elastic modulus(KPa); renal group represented in order across 
x-axis, Normal, Mild, Severe; scale on y-axis in KPa. 
Mild   Moderate            Severe  
Mild   Moderate            Severe  
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Figure 27: Box plot of intima media thickness per renal group 
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Legend: IMT=intima media thickness; renal group represented in order across x-axis, 
Normal, Mild, Severe. Scale on y-axis in mm.  
 
Figure 28: Box plot of pulse pressure per renal group 
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Legend: PP=pulse pressure; renal group represented in order across x-axis, Normal, 
Mild, Severe. Scale on y-axis in mmHg. 
Mild   Moderate            Severe  
Mild   Moderate            Severe  
P
ul
se
 p
re
ss
ur
e 
(m
m
H
g)
  
(m
m
) 
110 
 
Discussion 
In line with other published studies investigating the relationship between 
arterial stiffness and renal disease, we have shown that age, 
cardiovascular disease, hypertension and hyperlipidaemia as well as 
indices of arterial stiffness are significantly related to renal dysfunction.256 
However we found that the change in arterial stiffness was most marked 
between the Normal group and the Mild group, whereas the remainder of 
these parameters (with the exception of age) were not found to be 
significantly changed until a comparison was made with subjects with the 
Severe group. These findings remained significant when further statistical 
analysis between the Normal and Mild group was made using logistic 
regression. Similar analysis between the Mild and Severe group 
suggested that only age and E was significantly associated. 
The difference in E and Ep between the Normal and Mild group 
suggests that that there is an increase in both the material and overall 
structural stiffness of the arterial wall early in the development of renal 
disease. This may occur before other markers of cardiovascular disease 
are apparent such as increased pulse pressure or development of 
increased IMT or arterial diameter. This may be because the observed 
increase in arterial wall stiffness in subjects with renal disease occurs due 
to different mechanisms from that found in a normal population. Putative 
mechanisms include changes in the quantity30 and elasticity181 of 
extracellular collagen together with medial calcification.182  
111 
 
Increased Carotid IMT secondary to hypertension and wall stress 
has been noted in CKD patients,30 but this may be a late change, as we 
did not find any significant increase in this in our study. It is interesting 
that the statistically significant difference in Ep but not E was lost in our 
regression model looking at the Mild and Severe group, as this suggests 
continued change in the material stiffness of the arterial wall as CKD 
progresses, but not a resultant change in overall structural stiffness. 
The numbers involved in this retrospective study are small and our 
findings need validation via a larger prospective study. In particular this 
would permit further regression analysis with a more complex model than 
the one used in our study (age, sex and diabetes). In addition we 
recruited three distinct groups of subjects with normal renal function, mild 
renal impairment and severe renal impairment. Thus was a flaw in our 
study design as this study would have yielded more information if the 
study population included subjects with all CKD stages and thus a full 
spectrum of eGFRs. We did not include any subjects receiving renal 
replacement therapy as we believed it likely that dialysis would cause too 
much flux in data collection to be valid. 
Conclusions  
This study has shown a statistically significant increase in both E and Ep 
when comparing healthy subjects with mild renal disease. This was not 
the case for IMT or PP. This finding was maintained for Ep but not E in a 
comparison of subjects with mild and severe renal disease, suggesting 
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that there is continued change in material arterial wall stiffness as CKD 
progresses although this may not manifest as increased overall structural 
stiffness.  
We believe that therapies to target the early change in wall 
stiffness may be the key to diminishing the high prevalence of 
cardiovascular disease found in subjects with CKD, as it may be too late 
in the disease process to attempt to reverse in reaction to other changes 
such as increased IMT and PP and still expect a significant decrease in 
the prevalence of cardiovascular disease in subjects with CKD. 
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12 
ACE INHIBITORS INCREASE TYPE III 
COLLAGEN SYNTHESIS: A POTENTIAL 
EXPLANATION FOR REDUCTION IN ACUTE 
VASCULAR EVENTS BY ACE INHIBITORS 
Large trials have shown that Angiotensin Converting Enzyme Inhibitor (ACE-I) therapy 
reduces the risk of myocardial infarction and stroke. Acute vascular events are thought 
to be initiated by plaque rupture. Animal models of atherosclerosis show an increase in 
extra cellular matrix when given ACE-I therapy. ACE-I therapy could influence collagen 
synthesis, one of the major constituents of the atherosclerotic cap. 
Subjects were assessed for arterial disease, drug history and smoking. Blood 
samples were taken for a measure of collagen synthesis, the amino-terminal propeptide 
of type III procollagen (PIIINP), lipid levels, iron metabolism and cotinine levels. 
Information was available for 420 subjects. 35 were taking ACE-I therapy and 385 were 
not. Mean serum PIIINP level was 3.5 μg/l (SD 1.3 μg/l, range: 1.7 μg/l to16.5 μg/l.  
There was a marked increase in mean collagen turnover between subjects taking ACE-I 
therapy compared to those not. Mean PIIINP level for cases and controls was 4.26 μg/l 
(95% CI: 3.73 – 4.79 μg/l) versus 3.61 μg/l (95% CI: 3.48 – 3.75 μg/l). After adjusting for 
age, weight, height, lipid levels and ferritin, PIIINP levels remained significantly higher in 
cases than controls: 4.14 μg/l (95% CI: 3.72 – 4.57 μg/l) versus 3.62 μg/l (95% CI: 3.49 
–3.75 μg/l) (P value 0.02). 
These results suggest that ACE-I therapy up regulates collagen synthesis, and 
could improve plaque stabilisation. This may provide an explanation for the decrease in 
acute vascular events observed in patients on ACE-I therapy. 
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Introduction 
Several large trials have shown that treatment with ACE inhibitors 
significantly reduces the risk of myocardial infarction and stroke. This 
effect was demonstrated to be independent of reduction in blood pressure 
and concomitant medication.262 It is thought that most acute vascular 
events begin with rupture of an atherosclerotic plaque. This suggests that 
ACE inhibitors lower the risk of atherosclerotic plaque rupture.  
Unstable plaques, at higher risk of rupture, tend to have a thin, 
friable fibrous cap. The cap consists of extra cellular matrix, the chief 
component of which is collagen. Type I and III are the major structural 
components that confer tensile strength to the fibrous cap. 263,264 Type III 
is also the major component of large arteries, muscle and skin.265,266 
Collagen homeostasis is determined by the opposing metabolic 
processes of collagen synthesis and collagen degradation. A large 
amount of research has implicated increased matrix metalloproteinase 
(MMP) activity as an important factor in increased collagen 
degradation.267-269 However, it is important to consider increased collagen 
synthesis as well. This study was performed to investigate the effect of 
ACE-Is on collagen type III synthesis. 
The hypothesis was that subjects taking ACE-Is would have 
increased collagen type III synthesis when compared to a matched 
control population. 
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Methods 
Subject selection 
A screening programme for asymptomatic abdominal aortic aneurysms in 
males over the age of 50 started in Huntingdon, England in November 
1991. The cohort of screened men over the age of 50 living in the 
Huntingdon District served as a basis for this study. All subjects 
underwent informed consent, and ethical approval was gained locally. All 
subjects were interviewed about their family history, previous medical 
history, drug history, and smoking habits. All subjects had a brief medical 
examination by the same observer. The medical examination included 
measurement of the ABPI and the aortic diameter by ultrasound. PAD 
was deemed present if the ABPI was less than 0.9. An aneurysm was 
defined as an infrarenal aortic diameter of 3 cm or more. 
A blood sample was taken from all patients for measurement of 
serum collagen turnover, lipid levels, markers of iron metabolism and 
cotinine levels. Smoking and cholesterol are standard risk factors for 
atherosclerotic disease and acute vascular events. Therefore 
measurements of serum cotinine levels and lipid levels allowed us to 
adjust for possible differences in the distribution of those risk factors 
between the groups exposed to ACE inhibitors and those not exposed. 
Markers of iron metabolism were measured as iron is an important 
cofactor in collagen metabolism.265,266 These markers consisted of serum 
iron, transferrin, ferritin and antichymotrypsine levels. 
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Blood samples were taken at the time of the medical examination. 
They were spun down and the serum frozen at -21°C on the same day for 
analysis later. Batches of 74 serum samples were analysed in duplicate 
on the same day, by the same biochemist from the Department of 
Chemical Pathology in Hinchingbrooke Hospital. The concentration of the 
amino-terminal propeptide of type III procollagen (PIIINP) was used as a 
proxy measure of type III collagen turnover. The amino-terminal 
propeptide is split from the procollagen molecule during type III collagen 
synthesis.265,266 The concentration of PIIINP was measured using an 
equilibrium type serum radio-immunoassay for the amino-terminal 
propeptide of type III procollagen. This was based on highly purified 
specific human antigen (Pharmacia & Upjohn Ltd, Diagnostics Division, 
Milton Keynes, UK) and performed according to the instructions of the 
manufacturer with the use of duplicate 200 μL aliquots of serum.270,271 
The assay detects the authentic amino-terminal propeptide of type III 
collagen, but is not sensitive to the smaller degradation products of the 
propeptide.270 The antigens are resistant to repeated thawing and 
freezing.271The benefit of this assay is that standard and human serum 
samples give parallel inhibition curves allowing more accurate reading of 
serum levels without the need for repeated dilution and analysis.270 The 
intra-assay and inter-assay coefficients of variation of this assay are less 
than 5% and the sensitivity is 0.2 μg/L. The reference range for adults, 
based on data of Finnish blood donors was 1.7 to 4.2 μg/L, with no 
differences between males and females.270 The lipid profile consisting of 
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serum total cholesterol, HDL cholesterol, LDL cholesterol and 
triglycerides was determined using an automated procedure on a random 
blood sample. Blood samples were taken during clinic attendance. 
Screening clinics were in the evening at 5pm or on Saturday morning. No 
instructions about food intake were given prior to the medical 
examination. Lipid profiles were measured within a few days in the 
Department of Chemical Pathology at Hinchingbrooke Hospital, as part of 
their standard routine lipid assays. Total cholesterol, HDL cholesterol, 
LDL cholesterol and triglycerides were measured using standard 
enzymatic methods in a fully automated procedure using a Roche Hitachi 
717 analyser with Bio Stat reagents. Serum cotinine levels were 
measured using a standard semi-quantitative microplate enzyme 
immunoassay (Cozart Biosciences, Abingdon, UK).  
 
Statistical Analysis 
Mean values were compared using a t-test. Multivariate analysis was 
performed using linear regression methods272 with STATA 5.0 for 
Macintosh.273 Adjusted mean PIIINP levels were calculated using logistic 
regression models.274 Adjusted means were compared using Fisher's F 
test. 
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Results 
Assessment of collagen turnover in the form of PIIINP levels was 
available for 456 subjects. Detailed information about medication and 
PIIINP levels were available for 420 subjects. Of these 420 subjects, 180 
had no evidence of PAD and no aneurysmal disease, 34 had evidence of 
PAD but no aneurysmal disease, 129 had a small aneurysm (30 - 45mm 
diameter) but no evidence of PAD, 60 patients had both a small 
aneurysm and PAD and in 17 patients data about PAD were missing. 
They were included in the study. 35 subjects were on ACE inhibitors and 
385 were not. Mean serum PIIINP level was 3.5 μg/l (SD 1.3 μg/l). A large 
variation in PIIINP levels was found, range: 1.7 μg/l to 16.5 μg/l. There 
was a significant increase in mean collagen turnover between subjects on 
ACE inhibitors compared to those not on ACE inhibitors. Mean PIIINP 
levels for subject on ACE inhibitors was 4.26 μg/l (95% CI: 3.73 – 4.79 
μg/l), compared to 3.61 μg/l (95% CI: 3.48 – 3.75 μg/l) for subjects not 
exposed to ACE inhibitors. Mean PIIINP levels of the 36 subjects with 
missing data about current medication was 3.78 μg/l (95% CI: 3.30 – 4.27 
μg/l). There were no statistically significant differences in type III collagen 
turnover between subjects on other anti-hypertensive drugs such as: 
calcium channel blockers, diuretics or betablockers (see Table 14). There 
were no significant differences in PIIINP levels between subjects with a 
small aneurysm (mean PIIINP: 3.73 µg/L 95% CI 3.53 – 3.93) and 
subjects with a normal aorta (mean PIIINP: 3.63 µg/L 95% CI 3.47 – 3.79) 
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(P value .46). There were no significant differences in PIIINP levels 
between subjects with evidence of PAD (mean PIIINP: 3.71 95% CI 3.47: 
– 3.95) and subjects with no evidence of PAOD (mean PIIINP: 3.65µg/L 
95% CI: 3.50 – 3.80) (P value .71). The difference in collagen turnover 
remained significant after adjusting for presence of aneurysmal disease 
or evidence of PAOD. Adjusted mean PIIINP for subjects on ACE 
inhibitors was 4.27 µg/L, (95% CI 3.83 – 4.71 compared to a mean PIIINP 
of 3.59 µg/L, (95% CI 3.46 – 3.73 for those not on ACE inhibitors (P value 
.0046). 
Stepwise regression was used to investigate which other variables 
were associated with PIIINP levels. Variables investigated were age, 
height, weight, systolic and diastolic blood pressure, diabetic status, 
smoking status in the form of serum cotinine levels, and the usual 
standard lipid risk factors such as: total cholesterol levels, HDL 
cholesterol, LDL cholesterol and triglycerides. Iron is an important 
cofactor of collagen metabolism. We also investigated the following 
measurements of iron metabolism: serum iron levels, transferrin levels, 
ferritin levels and antichymotrypsine. Stepwise regression showed that 
PIIINP levels were significantly associated with age, height, weight, 
diastolic blood pressure and ferritin levels. None of these were 
significantly different between subjects on ACE inhibitors and those not 
on ACE inhibitors (see Table 15). We calculated adjusted mean PIIINP 
levels between subjects exposed to ACE inhibitors and those not 
exposed. The difference in mean PIIINP levels remained significant after 
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adjusting for age, height, weight, HDL and ferritin: 4.14 mcg/l (95% CI: 
3.72 – 4.57 mcg/l) for subjects exposed to ACE inhibitors versus 3.62 
mcg/l (95% CI: 3.49 –3.75 mcg/l) (P value 0.02).  
 
Table 14: Collagen turnover as measured by serum PIIINP concentration 
between subjects exposed to classes of anti hypertensive drugs and 
those not exposed. 
drug number 
exposed 
mean PIIINP
 
number 
not 
exposed 
 
mean PIIINP 
 
P value
ACE -I 35 4.26 
(3.73 - 4.79) 
 
378 3.62 
(3.49 - 3.76) 
0.007 
Ca channel 45 3.53 
(3.25 - 3.82) 
 
368 3.70 
(3.56  -3.84) 
0.65 
diuretics 64 3.95 
(3.61 - 4.30) 
 
349 3.63 
(3.49 - 3.77) 
0.08 
betablockers 77 3.80 
(3.52 - 4.08) 
 
336 3.65 
(3.51 - 3.80) 
0.25 
Legend: PIIINP levels in mcg/L, with 95% confidence levels in brackets; p values were 
calculated by applying the t-test to the log transformation of the mean PIIINP between 
subjects exposed to classes of anti hypertensive drugs and those not exposed. 
 
Table 15: Confounding variables associated with PIIINP levels and the 
differences between subjects on ACE-I and those not. 
variable on ACE-I not on ACE-I P value 
age  
70.7 
 (68.5 – 73.1) 
 
 
70.8 
 (70.1 – 71.6) 
 
 
0.95 
height (cm) 172.1  
(170.1 – 174.1) 
 
173.5  
(172.8 – 174.2) 
0.24 
weight (kg) 81.6  
(76.9 – 86.3) 
 
80.1  
(79.0 – 81.3) 
0.49 
HDL (mmol/l) 1.05 
 (0.95 – 1.14) 
1.16  
(1.11 – 1.21) 
 
0.20 
Ferritin (mcg/l) 136.9  
(101.1 – 172.8) 
118.4  
(108.4 – 128.3) 
 
0.29 
Legend: HDL=high density lipoprotein cholesterol; figures in brackets are 95% 
confidence intervals 
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Discussion 
A marked increased type III collagen synthesis, as measured by PIIINP 
levels, was seen in subjects on ACE-Is compared to those not exposed to 
ACE-Is. The difference was highly significant and remained significant 
after adjusting for confounding variables.  
Marshall et al275 demonstrated a reduction in collagen metabolism 
in lung tissue after administration of intratracheal Ramipril (an ACE-I) and 
Losartan (an Angiotensin II type 1 antagonist). This finding was also 
noted in their control population where intratracheal saline was 
administered. There was also clear evidence that ACE was not the only 
controlling factor for Angiotensin II expression in this experiment. 
Another in vitro experiment276, this time utilising rat cardiac cells, 
investigated the role of  N-Acetyl-Seryl-Aspartyl-Proline (Ac-SDKP), a 
natural inhibitor of stem cell entry into S phase (the period for collagen 
synthesis).This molecule  is hydrolysed by ACE-Is. They found it to have 
a biphasic and dose dependant effect on collagen synthesis. In low doses 
it had an inhibitory effect on collagen synthesis, but in high dose no 
significant effect was noted. 
The use of ACE-Is in other animal models of atherosclerosis has 
shown a decrease in plaque area with a decrease in macrophage 
accumulation. An increase in the extracellular matrix was also 
demonstrated.277 These phenomena could be explained by the up 
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regulation of collagen synthesis, and the presence of increased quantities 
of collagen in the fibrous cap. 
Reduced collagen content in the fibrous cap may result from 
decreased synthesis of the extra-cellular matrix by VSMCs, increased 
breakdown, or both. VSMCs synthesize the precursors of type III collagen 
for the extracellular matrix. The synthesis and degradation of the 
extracellular matrix proteins are slow in the normal artery. Atherosclerosis 
and arterial injury lead to increased synthesis of many matrix components 
including collagen type III,277 presumably as part of the response to the 
insult. 
Conclusions 
These results suggest that ACE-I therapy may increase collagen 
synthesis, and thus plaque stabilisation. This may provide an alternative 
explanation for the decrease in acute vascular events observed in 
patients on ACE-I therapy. 
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13 
ASSESSMENT OF CAROTID ARTERY STIFFNESS 
AND COLLAGEN TURNOVER IN SUBJECTS WITH 
PERIPHERAL ARTERIAL DISEASE COMMENCED 
ON RAMIPRIL. 
ACE-Is cause a reduction in secondary cardiovascular events, independent of blood 
pressure.  This may be secondary to vascular remodelling. In chapter 12 we have 
demonstrated that ACE-I administration in subjects with PAD is associated with 
increased collagen turnover. The aim of this chapter was to carry out a longitudinal study 
into the effects of ACE-I administration in subjects with PAD. 
33 subjects with confirmed PAD were recruited into the study, and were 
commenced on Ramipril. PIIINP, BP, IMT, d, E and Ep were measured at baseline, 
12week, 26wekks and 52 weeks. 13 completed the entire study. At 52 weeks, PIIINP 
levels were significantly higher (2.14 versus 2.67 p= 0.018), together with a significant 
decrease in SBP (159 versus 142 mmHg p= 0.011), IMT (1.24 versus 0.93 mm p=0.003) 
and diameter (8.51 versus 6.90mm p=0.013). Ep was significantly less at 26 weeks but 
not at 52 weeks, and E was significantly less at 12 weeks but not thereafter.  
We have shown statistically increased collagen turnover as estimated by PIIINP 
levels in subjects with PAD commenced on Ramipril. However the subject population 
was small with a high dropout rate. Therefore whilst the results may not be valid, they 
confirm our hypothesis of chapter 12 and warrant further study.  
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Introduction 
The significant reduction in  secondary cardiovascular events seen in 
subjects taking Ramipril who have cardiovascular disease is well 
recognised from large epidemiological studies.262 This effect is 
independent of blood pressure reduction and may well be secondary to 
vascular remodelling and plaque stabilisation, together with reduction of 
large artery stiffness.159 The RAAS has long been implicated in subjects 
with arterial hypertrophy secondary to hypertension. Increased lumen 
size, IMT, collagen deposition and decreased compliance have all been 
noted.278-280 Collagen homoeostasis may be influenced by inhibition of 
MMPs on the basis that ACE-Is bind zinc, a cofactor for a number of 
MMPs.281 Using the amino terminal pro-peptide of type III procollagen 
(PIIINP) as a marker of collagen turnover, previous results suggest that 
collagen synthesis is increased in subjects taking ACE-Is (see chapter 
12). However we recognize that this finding needs to be confirmed in a 
prospective study. Ahimastos et al have shown decreased arterial 
stiffness in a case control study subjects with PAD given Ramipril as 
opposed to placebo. They also demonstrated that Ramipril promoted 
elastogenic remodelling in cell cultures.159 Decreased arterial stiffness 
from baseline in subjects commenced on Ramipril would provide further 
evidence to support the presence of non anti-hypertensive beneficial 
effects of ACE-Is. 
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The aim of this study was to measure collagen turnover and 
arterial stiffness in a cohort of subjects with PAD who were commenced 
on Ramipril. 
The hypothesis was that collagen synthesis would increase and 
that arterial stiffness would decrease over time in these subjects when 
commenced on Ramipril.  
 
Methods 
Subject Selection 
Ethical approval was obtained for this study from the East Birmingham 
Research and Ethics Committee. Subjects were recruited from the 
vascular surgical outpatients clinics of Heart of England NHS foundation 
trust and provided written informed consent. All subjects had a confirmed 
diagnosis of PAD based on history and ABPI of less than 0.9 in at least 
one leg. Patients were excluded from the study if already taking an ACE-I 
or Angiotensin II receptor blocker (A2RB), had abnormal renal function or 
a history of renal artery stenosis (RAS). Subjects entered into the study 
were commenced on Ramipril starting at 2.5 mg for one week, 5 mg for 
three weeks and increased to the maintenance dose of 10 mg thereafter. 
Arterial stiffness and collagen turnover was assessed at baseline, at 12 
weeks, 26 weeks and 52 weeks. 
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Measurement of collagen turnover 
Blood samples were taken at the specified intervals. They were spun 
down and the serum frozen at -21°C on the same day for subsequent 
analysis. The serum samples were analysed in duplicate on the same 
day, by a single biochemist from the Department of Pathology at the 
Heart of England NHS Foundation Trust. The method used was exactly 
the same as that described on page 118. 
Statistical analysis 
 
After extraction and collation of the raw data using Microsoft Excel, the 
data were analysed using Stata 8.1 for Windows (STATA Stata 
Corporation, College Station, Texas, USA). Measurements at 12, 26 and 
52 weeks of arterial stiffness indices, PIIINP, IMT, diameter and blood 
pressure were examined for significant differences with baseline 
measurements using Wilcoxon signed ranks. 
Results 
33 subjects were recruited into the study. However 20 of the subjects 
were unable to complete the trial period, either being non compliant with 
the study drug or being lost to follow-up. The main demographics are 
demonstrated in Table 16, pre-existing medication in Table 17. At 52 
weeks, PIIINP levels were significantly higher (2.14 versus 2.67 p= 
0.018), together with a significant decrease in SBP (159 versus 142 
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mmHg p= 0.011), IMT (1.24 versus 0.93 mm p=0.003) and diameter (8.51 
versus 6.90mm p=0.013). Ep was found to be significantly less at 26 
weeks but not at 52 weeks, and E was found to be significantly less at 12 
weeks but not thereafter (Table 18). Figures 29-34 show box plots of all 
of these variables.  
 
Table 16: main demographics of ARC Study population 
variable age 
 
male smoking HTN CAD CVD DM 
 68 
(51-84) 
39 
(76) 
29 
(57) 
28 
(55) 
4 
(8) 
1 
(2) 
8 
(16) 
 
Legend HTN = hypertension; CAD = coronary artery disease; CVD = cerebrovascular 
disease; DM = diabetes mellitus; figure in brackets is percentage of prevalence in whole 
study population except for age where figure is range in years. 
 
Table 17: drug history for ARC study population 
drug Statin diuretic ca antagonist nitrate b-blocker 
 
 43 
(84) 
 
8 
(16) 
9 
(18) 
1 
(2) 
3 
(6) 
Legend: figure in brackets is percentage of prevalence in whole study population.  
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Table 18: Mean values for parameters in ARC study population. 
variable start 12wks 26wks 52wks 
 
 
no of 
subjects 
 
 
33 
 
23 
 
20 
 
13 
PIIINP 2.41 
(0.76-5.90) 
 
2.62 
(0.53-7.24) 
0.112 
2.36 
(0.46-4.87) 
0.724 
2.65 
(1.38-3.83) 
0.050 
SBP 152 
(106-203) 
145 
(113-194) 
0.002 
139 
(116-168) 
0.000 
142 
(134-149) 
0.000 
 
IMT 1.13 
(0.66-1.83) 
 
1.07 
(0.71-1.56) 
0.000 
 
0.87 
(0.30-1.44) 
0.000 
0.92 
(0.78-1.11) 
0.000 
d 8.38 
(5.58-10.54) 
7.67 
(6.00-10.00) 
0.000 
7.11 
(5.14-10.04) 
0.000 
7.08 
(5.40-8.55) 
0.000 
 
Ep 324 
(75-2309) 
 
231 
(63-1314) 
0.007 
147 
(87-245) 
0.001 
185 
(98-342) 
0.004 
 
E 1301 
(251-7425) 
3925 
(1092-15237) 
0.000 
 
684 
(234-2034) 
0.001 
714 
(349-1481) 
0.001 
Legend: PIIINP = amino terminal pro-peptide of type III procollagen; SBP = 
systolic blood pressure; IMT = intima media thickness; d = diameter; Ep = elastic 
modulus; E = Young’s modulus; figures in brackets are 95% confidence 
intervals; figure in italics is p value comparing parameter with starting value. 
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Figure 29: Box plot of PIIINP levels 
 
Legend: blue= results at start; red= 12weeks; green= 26weeks; yellow= 52weeks; y axis 
PIIINP (mcg/L) 
 
Figure 30: Box plot of change in intima media thickness 
 
Legend: blue= results at start; red= 12weeks; green= 26weeks; yellow= 52weeks; y axis 
IMT (mm) 
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Figure 31: Box plot of diameter 
 
Legend: blue= results at start; red= 12weeks; green= 26weeks; yellow= 52weeks; y axis 
diameter (mm) 
 
Figure 32: Box plot of systolic blood pressure 
 
Legend: blue= results at start; red= 12weeks; green= 26weeks; yellow= 52weeks; y axis 
SBP (mmHg) 
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Figure 33: Box plot of Young’s modulus 
 
Legend: blue= results at start; red= 12weeks; green= 26weeks; yellow= 52weeks; y axis 
E (kPa) 
 
Figure 34: Box plot of Elastic modulus 
Legend: blue= results at start; red= 12weeks; green= 26weeks; yellow= 52weeks; y axis 
E (kPa) 
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Discussion 
We have shown in a cohort of subjects with PAD that administration of 
Ramipril results in a statistically significant increase in PIIINP turnover 
and a statistically significant decrease in SBP, IMT and diameter. Both E 
and Ep demonstrated statistically significant transient decreases during 
the one year follow-up period, with Ep significantly decreased at 26 
weeks and E significantly decreased at 12 weeks. 
 Initially we intended to recruit over 50 subjects into the study, but 
we were only able to recruit 33 in the allocated study period (18 months) 
mainly due to the lack of perceived benefit from starting Ramipril in the 
recruitment population and the requirement to visit the research facilities 
separately from other clinic visits in order to have ultrasound scans and 
blood sampling. These factors also resulted in high dropout of the initial 
recruitment population such that only 13 (39%) of the subjects initially 
enrolled into the study were compliant with the study drug and attended 
follow-up. Interestingly, few subjects cited side-effects as the reason for 
the lack of compliance with the study drug.  As a result we believe that 
the sample population is too small to draw any meaningful conclusions or 
to accept that statistical analysis outlined in the results section as the 
probability of a type 2 statistical error is very high. We still believe that 
there is merit in investigating arterial stiffness parameters in subjects with 
PAD commenced on Ramipril, but the size and the duration of the study 
would need to be increased together with increased convenience of data 
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collection so that this study population which is likely to be attending 
outpatient clinics on a regular basis is not further inconvenienced by extra 
visits.  
 The crossover study design which was used, whilst well 
recognised as a method to investigate the effect of a treatment on 
subjects with chronic disease, clearly has limitations. This study could 
have been designed using a placebo and intention to treat analysis. It 
would have been more difficult to set up and would require a full dataset 
for analysis but could potentially have overcome some of the limitations of 
the crossover design. 
 
Conclusions 
Whilst we have shown statistically increased of collagen turnover as 
estimated by PIIINP levels in subjects with PAD commenced on Ramipril, 
the size of the initial subject population was small. Together with poor 
compliance in terms of both follow up attendance and drug 
administration, we are not able to draw any meaningful conclusions from 
these results. However these preliminary results confirm our hypothesis 
of chapter 12 and warrant further study. 
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14 
GENERAL DISCUSSION 
The central hypotheses of this thesis are that the TDI system is able to 
provide a high resolution plot of the ADW that has acceptable 
reproducibility when calculating indices of arterial stiffness. This should 
then permit a detailed and accurate analysis of indices of material and 
structural arterial wall stiffness to show changes in these indices in 
subjects with increasing age, PAD, CKD and subjects with PAD 
commenced on Ramipril, when compared to healthy controls. I believe 
that I have demonstrated this to be the case in the preceding chapters. 
It took a long time to develop the technique to be able to reliably 
capture the ADW. There were two main reasons for this.  Initially the 
offline software analysis of the cineloops containing TDI data produced 
unreliable and confusingly inaccurate results that suggested at times that 
the system might have poor reproducibility and at other times that it might 
not work at all (for example failing to identify any arterial wall movement 
at all when this was clearly seen by the naked eye on the cineloop). 
 Trial and error suggested that the main reason for this was 
movement of the ultrasound probe head which resulted in poor scan 
plane alignment while cineloops were captured.  Thus the maximum 
excursion of the arterial wall during the arterial distension waveform was 
not captured along the entire length of the region of interest (ROI) of the 
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insonated artery. As a result there was disparity in the ADW both along 
the ROI and from cardiac cycle to cardiac cycle.  I first saw the TDI 
system working in a lab based setting, with the probe held in clamp and 
the target an arterial phantom. This error was not present in the phantom 
based model and at first I believed that the disparity was due to biological 
variation in the ADW as opposed to poor insonation. This was particularly 
the case given that the second investigator had over eight years 
experience in ultrasound and the cineloops that he captured were of 
similar quality to mine (I had very little experience in ultrasound before 
starting research). It was only when we achieved scan plane alignment by 
ensuring that the intima-media complex was uniformly visible across the 
ROI during the whole time of cineloop capture that we started to get 
meaningful and reproducible results. Achieving scan plane alignment  is a 
basic requirement of good sonographic technique. Most dynamic velocity 
measurements using ultrasound in clinical practice provide immediate 
feedback of change in scan plane alignment via loss or dampening of the 
waveform. This feedback loop is not present in the TDI system and thus it 
is perhaps not surprising that this requirement took time to be identified 
as source of error together with finding a method reliably ensuring scan 
plane alignment for the entire duration of cineloop capture. 
Once reliable cineloops could be collected, it quickly became 
apparent that the TDI system generated a huge amount of data 
(Appendix 2) which was very time consuming to analyse until the analysis 
macro  was written to speed this process up (Appendix 2). It was only at 
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this point that we were able to start investigating the potential of the TDI 
system. 
We chose to assess arterial stiffness using Peterson’s elastic 
modulus and Young's modulus. These two indices were chosen after 
discussion with a medical physicist as they are the most widely accepted 
informative measures of wall stiffness, both within the field of medical 
physics and in the wider field of engineering as a whole. A major benefit 
of assessing arterial stiffness using a system such as the TDI based 
method is that it permits measurement of IMT and thus calculation of 
Young’s modulus. As previously discussed, there is discrepancy in the 
published literature as to the correct formula for Young's modulus. We 
worked back from first principles, with a medical physicist, in order to be 
sure which was the correct formula to use to analyse and interpret our 
results (Appendix 1, page 144). 
Assessment of arterial stiffness is based on elastic theory, which 
requires that the observed structure (in this case the arterial wall) is 
perfectly elastic and constructed from a homogenous and isotropic 
material.  The arterial wall, however, is viscoelastic, exhibiting both the 
properties of an elastic solid that regains its original form after a force 
applied to it is removed and a viscous liquid that maintains a deformity 
once the deforming force is no longer applied. The arterial wall 
heterogeneous, with the main elastic components being collagen and 
elastin, connected to a variable amount of smooth muscle all held in a 
liquid extracellular matrix, via a recognised 3 layer macroscopic structure. 
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In addition it may well be that the arterial wall moves anisotropically as 
opposed to isotropically (i.e. differently in different directions in response 
to the same stress). Thus the fundamental underlying principles by which 
elastic theory can be applied to arterial stiffness may be flawed. However 
almost all research on arterial stiffness uses elastic theory as it basis.6 It 
is considered that the viscous behaviour of the arterial wall is negligible 
when deforming stresses are applied slowly. If the arterial wall was 
examined as an anisotropic structure then a much greater amount of data 
would be required to be collected in order to calculate indices of arterial 
stiffness. As far as I am aware this is currently not practicable. 
A further weakness of our study is that carotid IMT is not a 
measurement of entire arterial wall thickness and represents the intima 
and the tunica media of the carotid artery.54 Both Pignoli and Wong have 
demonstrated that ultrasonic estimation of IMT was accurate when 
compared to histological verification, as long as the far wall of the 
insonated artery was examined, a practice that we have followed. Wong 
et al suggest that the adventitial layer contributes 25% of the thickness of 
carotid arterial walls by histological analysis, but that the adventitial layer 
is not recognised by ultrasound consistently or accurately.282,283 Clearly 
the adventitial layer of an artery has important mechanical properties. In a 
study of human femoral arteries, Schulze-Bauer estimated that the 
adventitial layer carried approximately 25% of the arterial wall load.284 In 
line with previous studies of this nature we have not attempted to correct 
for the lack of measurement of the adventitial layer in our estimation of 
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wall thickness.285 A change in wall thickness of 25% or less would not 
alter the statistical significance of our results, and it is widely accepted 
that most structural change in the arterial wall in response to ageing and 
development of atherosclerotic disease are believed to be in the intima 
and media.286, 287 Furthermore we used the same method of calculating 
the Young’s modulus in all our patient groups therefore avoided 
introducing systematic bias. 
The reproducibility of our measurements is at least as good as the 
best reported in the literature using conventional B-mode based 
techniques.240 The reproducibility is improved when compared to 
methods using echo tracking.241 The reason that the variability of our 
measurements of the arterial distension parameters is still around 10%  is 
because there is a finite variability of any biological parameter, and that 
despite measuring the arterial distension waveform with improved 
resolution, we had to use brachial arterial blood pressure measurement at 
systole and diastole as the only information available from the APW to 
calculate indices of arterial stiffness. More detailed information from the 
APW could lead to more reproducible measurements. 
When interpreting indices of arterial stiffness, in line with other 
studies of this nature we have used data from the left CCA only. This 
artery demonstrated superior reproducibility to the right in our 
reproducibility study.248 The left CCA is anatomically the most closely 
related to the aorta arising directly from the aortic arch as opposed to the 
right CCA which arises indirectly from the aorta via the brachiocephalic 
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trunk. Thus the left CCA is thought to be most likely to reflect the qualities 
of the central aorta. It is possible that this greater reproducibility is 
demonstrated because this artery is more comfortable for the investigator 
to insonate when the subject is approached from the patient’s right hand 
side.  
Towards the end of the research period, the Expert consensus 
document on arterial stiffness: methodological issues and clinical 
applications was published.14 We were pleased to note that the majority 
of the method we adopted for data collection was in accordance with this, 
despite carrying out the data collection before publication of this paper. 
This document divides methods of arterial stiffness calculation into three 
main types: systemic, regional and localised. The TDI based method is a 
localised method.  This method is recognised to have the benefits of 
direct determination requiring no model for calculation and is best suited 
for mechanistic analyses in pathophysiology, pharmacology and 
therapeutics, rather than for epidemiological studies.14 The document 
also recommends simultaneous measurement of local (in this case 
carotid) pulse pressure rather than use of brachial pressure. Previous 
studies have shown that using brachial artery pressure is a good 
substitute for carotid artery pressure when calculating carotid artery 
stiffness indices.288 Arterial pressure does vary throughout the arterial 
tree due to blood pressure amplification. Translation functions are 
available to estimate carotid pressures from other points in the arterial 
tree. Recent studies suggest that these are inaccurate especially as 
140 
 
amplification varies with age,289 and therefore brachial arterial pressure 
was used in this study. The expert consensus document also declares 
that carotid femoral PWV is the gold standard measurement of arterial 
stiffness based on simplicity and reproducibility, although it does also 
acknowledge that US based systems may provide better information 
regarding the arterial wall. We were pleased that the reproducibility of the 
TDI system is nearly as good as PWV (10.85% versus 8.3% for inter-
observer reproducibility and 10.16% versus 11.0% for intra-observer 
reproducibility). Whilst PWV is a direct measurement, calculation requires 
accurate estimation of arterial length (difficult in obese subjects or those 
with a large bust) between two transducers, both of which have to be 
fitted to the subject. This is not necessarily easier or quicker to carry out 
than an ultrasound scan of the common carotid artery and brachial artery 
blood pressure measurements. In addition, with the advent of high quality 
compact duplex machines, portability is not an issue. It did take the 
principal investigator just over one year to resolve all issues in order to 
produce reproducible data. However the second investigator was able to 
acquire these skills in just a few sessions once the technique was 
demonstrated to him, although he did have approximately eight years 
experience in ultrasound scanning.  
We have consistently shown that the changes in arterial stiffness 
are earlier or increased when compared to IMT. In some respects this is 
not surprising,given the likelihood that increased IMT is one of the earliest 
signs of atherosclerotic change. However our results do support the 
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premise that increased arterial stiffness is either a cause of 
atherosclerosis or one of the earliest indicators of its presence. This is 
important as there is no known treatment to reverse atherosclerosis. We 
need to target the development of atherosclerosis earlier than its 
manifestation via increased IMT or blood pressure. Understanding the 
relationship between arterial stiffness and atherosclerosis may be the key 
to this. 
Future Studies 
 Despite the fact that the TDI system is able to plot the ADW in 
detail, the only information we were able to use with regard to the arterial 
pressure waveform (APW) was systolic and diastolic pressure. We 
believe that the TDI method to measure the arterial distension waveform 
would show its full potential if coupled with effective technology that could 
simultaneously measure the arterial pressure waveform (APW).  The 
most commonly used device to do this non-invasively is the Portapres 
(www.finapres.com). This device measures and records the APW in the 
digits of either hand and together with non invasive brachial blood 
pressure measurements is able to provide a continuous calibrated APW. 
An applanation tonometer could provide the same information with the 
advantage of potential measurement of the carotid APW. If this was to be 
carried out, calibration would be required, presumably using brachial 
blood pressure and a translation algorithm. Used in conjunction with the 
TDI system, a full plot of the APW and ADW would allow calculation of 
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the relationship between pressure and distension at all physiological 
pressures. The gradient of the slope would be a true pressure 
independent measure of arterial stiffness, and could provide information 
about how stiffness in the arterial wall changes across the stress of the 
cardiac cycle. Potentially therefore a combination of both TDI and PWV 
May yield very detailed information, most appropriate in a research 
setting. Improved reproducibility may also be demonstrated.  
We were disappointed that our study looking at Ramipril and 
arterial stiffness in subjects with PAD failed due to recruitment and follow 
up issues. This was due to poor study design and time constraints, and 
we believe would yield important information to help explain the pressure 
independent cardiovascular benefits of Ramipril if carried out 
successfully. 
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Conclusions 
This thesis has demonstrated that the TDI-based system produces a high 
resolution plot of the ADW that has good reproducibility when used in 
conjunction with brachial blood pressure to calculate indices of arterial 
stiffness. We have shown that indices of structural and material arterial 
wall stiffness are more increased than IMT in studies comparing healthy 
subjects to those with PAD and CKD and with ageing. This suggests that 
increased arterial stiffness may be more than just a marker of 
cardiovascular disease that actually changes before atherosclerosis 
develops. 
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APPENDIX 1 :DERIVATION OF YOUNG’S 
MODULUS 
Pete Hoskin’s opinion 
Dear Martin 
 
As we have agreed, 
 
Ep (pressure strain) = (Ps-Pd) / [(Ds-Dd)/Dd]    (1)  
units are those of pressure is Pa (N/m2)  
    
McDondalds 1974, table 10.6  
gives an equation as part of its header, which is that  
E (Youngs) = Ep(pressure strain)*(R/h)     (2) 
Units are the same as Ep; ie Pa (N/m2) 
 
 
McDonald 5th edition  
E = Ep*(1/h) 
Units are Pa/m        (3) 
 
http://en.wikipedia.org/wiki/Young_Modulus  
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Youngs modulus is E = stress/ strain 
 
Or E = (F/A)/(x/l)        (4) 
units are Pa  
 
Discussion 
The units are a quick way to decide which is possibly correct and which is 
clearly wrong. Equation 4 shows the correct units, so equation 2 might be 
right, equation 3 is definitely wrong.  
In referencing this in your paper, I suggest that we forget about a 
history of definition and simply quote the article by Reneman. I would also 
not get into a discussion on previous definitions which have been wrong. 
This might come up at another time, but is not connected with our article, 
and we do not want to deflect or confuse the referees. Reneman is one of 
the major players in this general area; in a search I recently found some 
350 papers to his name! 
The maths that I provided last time was based on the article by 
Reneman, and the only difference between this and McDonald 1974 is a 
factor of 2. I have a grant to get in on Monday but I have forwarded this to 
Kate Fraser who you met who I will ask to check over the basic maths 
and we will get back to you on Tuesday or Wednesday this week. 
If you note the table in McDonald 5th edition looks to be a summary 
of some committee consensus. I am bit surprised that they made a 
mistake, but having done chapters in books, trying to tie down every 
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single equation is painful and there will be mistakes. Obviously we have 
found one. 
 
Best wishes 
Pete Hoskins  
 
 
 
 
 
147 
 
Kate Frasers Opinion 
Hi Martin, 
Pete is correct in that 
E = Ep * r / h 
I think the definition of E in McDonald 5th ed is based on a different 
definition of stress (using a thin walled approximation of the artery) and 
so probably isn't strictly wrong but is best avoided. 
I've come up with a straightforward derivation of E which shows how it 
relates to Ep - attached. 
(Pete - it might be a good idea if you check this through in case I've made 
any mistakes.) 
Hope that helps, 
Kate 
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Kate Fraser’s Derivation 
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APPENDIX 2 : OFFLINE COMPUTER ANALYSIS 
OF ARTERIAL SCANS 
Spreadsheet 
Each scan acquisition provided a data plot of over 20000 points as 
demonstrated in Figure 35. 
 
Figure 35: excel spreadsheet containing over 20000 data points from 
one scan of the CCA 
 
These data are shown graphically in Figure 36. 
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Figure 36: A graphical representation of arterial distension waveform  
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Legend: Dilations = how far in microns arterial wall moved apart during cardiac cycle; 
Scan line number= virtual line down which software calculated arterial wall dilatation (48 
line in total); Time = total length in time of scan and scale over which arterial dilatation 
occurred. This data was captured over 4 cardiac cycles from a segment of common 
carotid artery measuring approximately 2cm. 
 
Clearly this data needed summarising in order to be useful. This 
was done using a macro within Microsoft excel written using visual basic 
and is reproduced in the next section. The function of this macro is to 
summarise the data shown in Figures 35 and 36 and present it as ADC 
per cardiac cycle and per scan, together with between cycle variability 
within each scan. 
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Analysis Macro 
Sub ANALYSIS() 
' 
' ANALYSIS Macro 
' Macro recorded 10/06/2004 by Martin Claridge 
'' Keyboard Shortcut: Ctrl+q 
'    Range("H6").Select 
    ActiveCell.FormulaR1C1 = "ANALYSIS" 
    Range("H9").Select 
    ActiveCell.FormulaR1C1 = "CARDIAC CYCLE 1" 
    Range("H10").Select 
    ActiveCell.FormulaR1C1 = "CARDIAC CYCLE 2" 
    Range("H11").Select 
    ActiveCell.FormulaR1C1 = "CARDIAC CYCLE 3" 
    Range("H12").Select 
    ActiveCell.FormulaR1C1 = "CARDIAC CYCLE 4" 
    Columns("I:I").Select 
    Range("I4").Activate 
    Columns("H:H").EntireColumn.AutoFit 
    Range("I8").Select 
    ActiveCell.FormulaR1C1 = "MAX" 
    Range("J8").Select 
    ActiveCell.FormulaR1C1 = "MIN" 
    Range("H13").Select 
    ActiveCell.FormulaR1C1 = "AVERAGE" 
    Range("H14").Select 
    ActiveCell.FormulaR1C1 = "STD DEV" 
    Range("H15").Select 
    ActiveCell.FormulaR1C1 = "VARINCE" 
    Range("H15").Select 
    ActiveCell.FormulaR1C1 = "VARIANCE" 
    Range("I9").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[21]C:R[21]C[37])" 
    Range("I10").Select 
    ActiveWindow.SmallScroll ToRight:=-5 
    Range("I10").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[22]C:R[22]C[37])" 
    Range("I11").Select 
    ActiveWindow.SmallScroll ToRight:=-2 
    Range("I11").Select 
    ActiveCell.FormulaR1C1 = "=AVAERAGE(R[23]C:R[23]C[37])" 
    Range("I11").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[23]C:R[23]C[37])" 
    Range("I12").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[24]C:R[24]C[37])" 
    Range("I13").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[-4]C:R[-1]C)" 
    Range("I13").Select 
    ActiveWindow.SmallScroll Down:=5 
    ActiveWindow.SmallScroll ToRight:=-6 
    ActiveWindow.SmallScroll Down:=-3 
    Range("J9").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[22]C[-1]:R[22]C[36])" 
    Range("J10").Select 
    ActiveCell.FormulaR1C1 = "=avarage(R[23]C[-1]:R[23]C[36])" 
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    Range("J10").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[23]C[-1]:R[23]C[36])" 
    Range("J11").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[24]C[-1]:R[24]C[36])" 
    Range("J12").Select 
    ActiveCell.FormulaR1C1 = "=AVAERAGE" 
    Range("J12").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[25]C[-1]:R[25]C[36])" 
    Range("J13").Select 
    ActiveCell.FormulaR1C1 = "=AVERAGE(R[-4]C:R[-1]C)" 
    Range("K8").Select 
    ActiveCell.FormulaR1C1 = "difference" 
    Range("K9").Select 
    ActiveCell.FormulaR1C1 = "=RC[-2]-RC[-1]" 
    Range("K9").Select 
    Selection.AutoFill Destination:=Range("K9:K13"), Type:=xlFillDefault 
    Range("K9:K13").Select 
    Range("I14").Select 
    ActiveCell.FormulaR1C1 = "=STDEV(R[-5]C[2]:R[-2]C[2])" 
    Range("I15").Select 
    ActiveCell.FormulaR1C1 = "=R[-1]C/R[-2]C" 
    Range("I15").Select 
    Selection.NumberFormat = "0.00%" 
    ActiveWindow.SmallScroll Down:=-4 
End Sub 
Summary produced by analysis macro 
 
Figure 37 details the result produced by the analysis macro which was 
then used in further calculations. 
Figure 37: Results of analysis Macro. 
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